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Summary
Background Global development goals increasingly rely on country-specific estimates for benchmarking a nation’s 
progress. To meet this need, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016 estimated 
global, regional, national, and, for selected locations, subnational cause-specific mortality beginning in the year 
1980. Here we report an update to that study, making use of newly available data and improved methods. GBD 2017 
provides a comprehensive assessment of cause-specific mortality for 282 causes in 195 countries and territories from 
1980 to 2017.
Methods The causes of death database is composed of vital registration (VR), verbal autopsy (VA), registry, survey, 
police, and surveillance data. GBD 2017 added ten VA studies, 127 country-years of VR data, 502 cancer-registry 
country-years, and an additional surveillance country-year. Expansions of the GBD cause of death hierarchy resulted 
in 18 additional causes estimated for GBD 2017. Newly available data led to subnational estimates for five additional 
countries—Ethiopia, Iran, New Zealand, Norway, and Russia. Deaths assigned International Classification of Diseases 
(ICD) codes for non-specific, implausible, or intermediate causes of death were reassigned to underlying causes by 
redistribution algorithms that were incorporated into uncertainty estimation. We used statistical modelling tools 
developed for GBD, including the Cause of Death Ensemble model (CODEm), to generate cause fractions and cause-
specific death rates for each location, year, age, and sex. Instead of using UN estimates as in previous versions, 
GBD 2017 independently estimated population size and fertility rate for all locations. Years of life lost (YLLs) were 
then calculated as the sum of each death multiplied by the standard life expectancy at each age. All rates reported here 
are age-standardised.
Findings At the broadest grouping of causes of death (Level 1), non-communicable diseases (NCDs) comprised the 
greatest fraction of deaths, contributing to 73·4% (95% uncertainty interval [UI] 72·5–74·1) of total deaths in 
2017, while communicable, maternal, neonatal, and nutritional (CMNN) causes accounted for 18·6% (17·9–19·6), 
and injuries 8·0% (7·7–8·2). Total numbers of deaths from NCD causes increased from 2007 to 2017 by 22·7% 
(21·5–23·9), representing an additional 7·61 million (7·20–8·01) deaths estimated in 2017 versus 2007. The death 
rate from NCDs decreased globally by 7·9% (7·0–8·8). The number of deaths for CMNN causes decreased by 
22·2% (20·0–24·0) and the death rate by 31·8% (30·1–33·3). Total deaths from injuries increased by 2·3% 
(0·5–4·0) between 2007 and 2017, and the death rate from injuries decreased by 13·7% (12·2–15·1) to 
57·9 deaths (55·9–59·2) per 100 000 in 2017. Deaths from substance use disorders also increased, rising from 
284 000 deaths (268 000–289 000) globally in 2007 to 352 000 (334 000–363 000) in 2017. Between 2007 and 2017, 
total deaths from conflict and terrorism increased by 118·0% (88·8–148·6). A greater reduction in total deaths and 
death rates was observed for some CMNN causes among children younger than 5 years than for older adults, 
such as a 36·4% (32·2–40·6) reduction in deaths from lower respiratory infections for children younger than 
5 years compared with a 33·6% (31·2–36·1) increase in adults older than 70 years. Globally, the number of 
deaths was greater for men than for women at most ages in 2017, except at ages older than 85 years. Trends in 
global YLLs reflect an epidemiological transition, with decreases in total YLLs from enteric infections, respiratory 
infections and tuberculosis, and maternal and neonatal disorders between 1990 and 2017; these were generally 
greater in magnitude at the lowest levels of the Socio-demographic Index (SDI). At the same time, there 
were large increases in YLLs from neoplasms and cardiovascular diseases. YLL rates decreased across 
the five leading Level 2 causes in all SDI quintiles. The leading causes of YLLs in 1990—neonatal disorders, 
lower respiratory infections, and diarrhoeal diseases—were ranked second, fourth, and fifth, in 2017. Meanwhile, 
estimated YLLs increased for ischaemic heart disease (ranked first in 2017) and stroke (ranked third), even 
though YLL rates decreased. Population growth contributed to increased total deaths across the 20 leading 
Level 2 causes of mortality between 2007 and 2017. Decreases in the cause-specific mortality rate reduced the effect 
of population growth for all but three causes: substance use disorders, neurological disorders, and skin and 
subcutaneous diseases.
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Introduction
Systematic recording and analysis of causes of 
human death remains one of the most resilient successes 
for public health, beginning with routine and continuous 
reporting of deaths by physicians starting in the 
15th century.1 Today, hundreds of thousands of physicians 
evaluate and select the cause of death for millions of 
deaths annually, codifying the results according to the 
International Classification of Diseases (ICD) system.2 
These efforts form the basis of a global mortality 
reporting system that is widely relied upon to prioritise 
health system investments, track progress towards 
global development goals, and guide scientific research. 
Although there remains a need for wider adoption and 
improvement of these systems, continuous reporting of 
cause-specific mortality in many countries represents a 
success for global health.3
More mortality data are now becoming available 
because of broader adoption of vital registration 
systems and increased information-sharing made 
possible by digital communication. At the same time, 
efforts to correct, sort, analyse, and report this massive 
Research in context
Evidence before this study
Previously, the Global Burden of Diseases, Injuries, and Risk 
Factors Study (GBD) 2016 provided estimates for 264 causes of 
death for 195 countries and territories, by age and sex, from 1980 
to 2016. GBD 2016 incorporated newly available data for many 
locations, expanded and refined the included causes of death, 
improved modelling techniques, and developed a star rating 
system for the quality of cause of death data. To better assess 
mortality among the oldest adults, terminal age categories for 
age 90–94 years and 95 years and older were added. Other 
organisations periodically produce estimates of cause-specific 
mortality, including for a wide list of causes and across multiple 
age groups (WHO), for selected cancers (the International Agency 
for Research on Cancer), and for child deaths (the Maternal and 
Child Epidemiology Estimation [MCEE] group). GBD continues to 
provide the only peer-reviewed annual estimates of cause-specific 
mortality available for all locations over time.
Added value of this study
GBD 2017 includes estimates for 2017 and also updates the 
entire series from 1980 produced for GBD 2016. The list of 
included causes has been expanded and study methods have 
been improved in multiple ways. First, inclusion of an 
independent estimation of population and fertility developed 
for GBD 2017 substantially improved estimates in selected 
countries. Second, additional data were identified, including 
127 country-years of vital registration and ten verbal autopsy 
studies. Third, new subnational assessments were developed 
for five countries in 2017: Ethiopia, Iran, New Zealand, Norway, 
and Russia. Fourth, a new stratum was developed for 
subnational-level estimation in New Zealand to characterise 
populations by ethnicity as Māori or non-Māori. Fifth, we 
revised adjustments made for misclassified deaths due to 
dementia, Parkinson’s disease, and atrial fibrillation. Finally, 
additional diseases are now estimated, including 
non-rheumatic calcific aortic and degenerative mitral valve 
disease; subarachnoid haemorrhage; myelodysplastic, 
myeloproliferative, and other haemopoietic disorders; 
diabetes mellitus as type 1 and type 2 (previously combined); 
poisoning by carbon monoxide; liver cancer due to 
non-alcoholic steatohepatitis; ectopic pregnancy; and invasive 
non-typhoidal salmonella.
Implications of all the available evidence
Deaths due to communicable, maternal, neonatal, and 
nutritional causes continue to decline, while deaths from non-
communicable diseases increase and injury deaths are stable. 
Declines in death rates of some non-communicable diseases 
have slowed or ceased. GBD 2017 has increased its 
collaboration with governments, leading to additional data 
for subnational estimation. Engagement with GBD 
collaborators, policy makers, disease experts, and the public is 
guiding expansions of the cause list and resulting decreasing 
burden classified in residual “other” categories. 
Non-communicable diseases remain the leading causes of 
death globally, and their burden is rising. GBD 2017 is 
motivated by the same goals as GBD 2016, including the belief 
that annual updates, reflecting improvements due to 
improved data availability, new causes estimated, and better 
methods to reduce bias and improve transparency in 
reporting, are contributing to the formulation and tracking of 
new evidence-based health policy. We intend for GBD 2017 to 
serve as a global public good, freely available for policy makers 
and the public seeking to improve human health.
Interpretation Improvements in global health have been unevenly distributed among populations. Deaths due to 
injuries, substance use disorders, armed conflict and terrorism, neoplasms, and cardiovascular disease are expanding 
threats to global health. For causes of death such as lower respiratory and enteric infections, more rapid progress 
occurred for children than for the oldest adults, and there is continuing disparity in mortality rates by sex across age 
groups. Reductions in the death rate of some common diseases are themselves slowing or have ceased, primarily for 
NCDs, and the death rate for selected causes has increased in the past decade.
Funding Bill & Melinda Gates Foundation.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
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amount of global data are evolving to keep pace with 
increasing demands for timely assessment of global, 
regional, and local mortality patterns. In addition to 
shifts in mortality patterns due to an ongoing 
epidemiological transition, rapid spikes in mortality 
due to specific causes are frequently observed and 
require recurrent updates to global estimates. Examples 
of mortality spikes include opioid-associated deaths in 
parts of the USA,4 suicide in eastern Europe in the 
1990s,5 and conflict-associated deaths in the eastern 
Mediterranean and North Africa region.6 Causes of 
death are now reported digitally in many locations, 
allowing health authorities to improve the quality and 
timeliness of mortality reporting.7,8 Global development 
goals increasingly rely on country-specific estimates for 
benchmarking a nation’s progress. Global commitments, 
such as the UN’s Sustainable Development Goals 
(SDGs),9 the Moscow Declaration to End Tuberculosis,10 
WHO’s First Global Conference on Air Pollution and 
Health11 in October, 2018, and the UN High-level 
Meetings on NCDs12 and tuberculosis,13 both in 
September, 2018, will require ongoing tracking of 
cause-specific mortality, including in locations where 
mortality surveillance data remain limited.
The following study represents an annual update to 
the Global Burden of Diseases, Injuries, and Risk Factors 
Study (GBD), an effort to produce consistent and com-
parable estimates of cause-specific mortality for all 
locations globally. GBD 2017 includes results by age and 
sex, for the years 1980 through to 2017, for 195 countries 
and territories. A cycle of continuous quality improve-
ment has led to substantial changes, including new data 
sources, new causes of death, and updated methods. 
For the first time, population estimates have been 
independently produced by GBD 2017,14 and subna-
tional estimates have been produced for Ethiopia, Iran, 
New Zealand, Norway, and Russia. The purpose of GBD 
2017 is to serve as a global public good, freely available 
for policy makers and the public seeking to improve 
human health.
Methods
Overview
GBD cause of death estimation incorporates methods to 
adjust for incomplete or missing vital registration (VR) 
and verbal autopsy (VA) data, general heterogeneity in 
data completeness and quality, and the redistribution 
of so-called garbage codes (insufficiently specific or 
implausible cause of death codes). A general description 
of these methods is provided in this section, with further 
detail presented in appendix 1. GBD 2017 complied with 
the Guidelines for Accurate and Transparent Health 
Estimates Reporting (GATHER)15 statement (appendix 1 
section 1.3). Analyses were completed with Python 
version 2.7.14, Stata version 13.1, and R version 3.3.2. 
Statistical code used for GBD estimation is publicly 
available online.
Geographical units and time periods
The locations included in GBD 2017 have been arranged 
into a set of hierarchical categories composed of seven 
super-regions and a further nested set of 21 regions 
containing 195 countries and territories (appendix 1). 
Each year, GBD includes sub national analyses for a few 
new countries and continues to provide subnational 
estimates for countries that were added in previous cycles. 
Subnational estimation in GBD 2017 includes five new 
countries (Ethiopia, Iran, New Zealand, Norway, Russia) 
and countries previously estimated at subnational levels 
(GBD 2013: China, Mexico, and the UK [regional level]; 
GBD 2015: Brazil, India, Japan, Kenya, South Africa, 
Sweden, and the USA; GBD 2016: Indonesia and the UK 
[local government authority level]). All analyses are at the 
first level of administrative organisation within each 
country except for New Zealand (by Māori ethnicity), 
Sweden (by Stockholm and non-Stockholm), and the UK 
(by local government authorities). All subnational 
estimates for these countries were incorporated into 
model development and evaluation as part of GBD 2017. 
To meet data use requirements, in this publication we 
present all subnational estimates excluding those pending 
publication (Brazil, India, Japan, Kenya, Mexico, Sweden, 
the UK, and the USA); because of space constraints these 
selected subnational results are presented in appendix 2. 
Subnational estimates for countries with populations 
larger than 200 million (measured with our most recent 
year of published estimates) that have not yet been 
published elsewhere are presented wherever estimates 
are illustrated with maps but are not included in data 
tables.
The complete cause-specific estimation results include 
the years 1980 through to 2017, and are available for 
exploration by an online data visualisation tool. To better 
support current health policy assessment, we include a 
subset of analyses in the current study featuring the 
most recent interval, 2007–17. 
The GBD cause of death hierarchy
The GBD study attributes each death to a single 
underlying cause that began the series of events leading 
to death, in accordance with ICD principles. The GBD 
study organises causes of death in a hierarchical list 
containing four levels (appendix 1 section 7). At the 
highest level (Level 1), all disease burden is divided 
among three mutually exclus ive and collectively 
exhaustive categor ies: communicable, maternal, 
neonatal, and nutritional (CMNN) diseases; non-
communicable diseases (NCDs); and injuries. Level 2 
distinguishes these Level 1 categories into 21 cause 
groups, such as cardiovascular diseases; diarrhoeal 
diseases, lower respiratory infections (LRIs), and other 
common infectious diseases; or transport injuries. 
Level 3 disaggregates these causes further; in most 
cases this disaggregation represents the finest level of 
detail by cause, such as stroke, ischaemic heart disease, 
For the data visualisation tool 
see https://vizhub.health 
data.org/gbd-compare/
See Online for appendix 1
For the statistical code see 
https://github.com/ihmeuw/
ihme-modeling
See Online for appendix 2
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or road injuries. Where data are sufficiently available or 
specific policy relevance has been sought, selected 
causes are further disaggregated at Level 4, such as 
drug-susceptible tuberculosis, multidrug-resistant 
tubercu losis without extensive drug resistance, and 
extensively drug-resistant tuberculosis. For GBD 2017, 
the cause hierarchy was further refined to separately 
estimate causes with sub stantial policy interest or high 
levels of burden. Specific changes included separate 
estimation of non-rheumatic calcific aortic and degen-
erative mitral valve dis eases, and myelodysplastic, 
myeloproliferative, and other haemo poietic neoplasms, 
resulting in a reduction in the estim ates of some 
residual causes. Disaggregation of residual causes also 
allowed separate estimation of type 1 and type 2 diabetes, 
chronic kidney disease due to type 1 and type 2 diabetes, 
poisoning by carbon monox ide, liver cancer due to 
non-alcoholic steatohepatitis (NASH), subarachnoid 
haemorrhage, ectopic pregnancy, and invasive non-
typhoidal salmonella. Maternal and neonatal disorders, 
previously estimated as separate cause groupings at 
Level 2 of the hierarchy, were estimated for GBD 2017 
at Level 3 of the hierarchy, and then aggregated up to 
Level 2 to better capture the epidemiological connections 
and linked burden between them. The complete 
hierarchy of causes included in GBD 2017 and their 
corresponding ICD9 and ICD10 codes are described in 
appendix 1 (section 7).
Cause of death data
The GBD cause of death database consists of VR and VA 
data; survey and census data for injuries and maternal 
mortality; surveillance data for maternal mortality and 
child death; cancer registries; and police records for 
interpersonal violence and road injuries. Self-harm 
estimates incorporate VR data and are based on ICD 
categorisation as described in appendix 1 (section 7). In 
this iteration of GBD, ten new VA studies and 127 new 
country-years of VR data were added at the country 
level. 502 new cancer-registry country-years were 
added, as was one additional new surveillance country-
year. Data sources comprising the GBD cause of 
death database can be reviewed on the Global Health 
Data Exchange website. Multiple factors can influence 
changes between GBD studies in estimates for a given 
cause-location-year, including the quality of a country’s 
data system (as represented by the GBD star rating 
system) and the addition of more recent data. 
Figure 1 shows the relative stability of GBD estimates 
between study iterations. Variation between GBD 2016 
and GBD 2017 estimates was greater in countries with 
both low star ratings and no new VR data updates 
occurring between these iterations of the study. Changes 
to estimates can be seen even in high star rating 
locations because of changes in modelling strategy or 
model covariates even when no new VR data were 
available between cycles.
Data standardisation and processing
To standardise cause of death data, we used protocols 
to address the minor proportion of deaths that were 
assigned to age groups broader than the GBD five-year 
age groups or were not assigned an age or sex, and to 
address differences in ICD codes due to national 
variation or revision, as described in appendix 1 
(section 2). Garbage codes, deaths with non-specific 
codes (eg, unspecified stroke), deaths assigned to ICD 
codes that could not be underlying causes of death 
(eg, senility), or deaths assigned to intermediate but 
not underlying causes of death (eg, heart failure), were 
redistributed by age, sex, location, and year to the 
most likely causes of death. Methods used for this 
redistribution included regression models, redistri-
bution based on fixed proportions, pro portional 
reassignment, and fractional assignment of a death 
assigned to multiple causes, as developed by Naghavi 
and colleagues16 and detailed in appendix 1 (section 2.7). 
We excluded all data sources with more than 50% of 
deaths assigned to major garbage codes (those at 
Level 1 or Level 2 of the GBD hierarchy) in any location-
year to mitigate the potential for bias from these 
sources. The proportion of VR data assigned to major 
garbage code categories for each location-year is 
shown, with supporting detail, in appendix 1 (section 7). 
New to GBD 2017, the uncertainty around re-
distribution methods was also estimated. Additional 
details for this process are provided in appendix 1 
(section 2.7). Because mortality due to HIV/AIDS is 
sometimes coded to other causes of death such as 
tuberculosis, meningitis, or toxoplasmosis, we also 
corrected the cause of death assignment to HIV/AIDS 
for peak epidemic times. Tuberculosis deaths can be 
misclassified as pneumonia deaths in children in 
locations with a high tuberculosis burden. Methods to 
adjust for this potential mis classi fication are described 
in detail in appendix 1 (section 3.3).
Mortality rates from dementia and Parkinson’s disease 
reported in VR systems cannot be reconciled with 
observed trends in prevalence and excess mortality—a 
disparity that can be attributed to variation in death 
certification practices for these causes across countries 
and over time.17 For GBD 2017, we sought to address this 
known bias by using details from multiple cause of 
death data. For GBD 2017, multiple cause of death data 
were available to investigators only for the USA, where 
recent years show improved use of previously under-
utilised codes such as dementia. Statistical models of 
these USA data were used to reclassify deaths from 
other GBD causes and garbage codes to dementia and 
Parkinson’s disease according to the pattern of 
intermediate and immediate causes observed in the 
most recent years. Model results were applied to all 
countries. A similar reallocation pro cess was used for 
atrial fibrillation deaths misclassified as deaths due to 
heart failure or thromboembolic events. A detailed 
For the Global Health 
Data Exchange see 
http://ghdx.healthdata.org/
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description of these redistribution procedures and the 
manner in which they were applied to all countries is 
available in section 2 of appendix 1. This reallocation is 
illustrated in appendix 1 (section 7).
For the first time in GBD 2017, we separately estimated 
deaths from diabetes by type. Deaths due to diabetes can 
be reported in VR and VA data as type 1, type 2, or 
unspecified. Two data manipulation steps were necessary. 
First, we assumed all deaths reported in individuals 
younger than 15 years were type 1 regardless of the 
original code assignment. Second, we redistributed 
unspecified diabetes deaths on the basis of a regression 
in which the true proportions of type 1 and type 2 deaths 
by age-sex-location-year are a function of the proportion 
of unspecified deaths, age, the age-standardised pre-
valence of obesity, and an interaction term for age and 
obesity prevalence. These methods are described in detail 
in appendix 1 (section 3.3).
Figure 1: Effect of new VR data on Level 1 cause estimates from GBD 2016 to GBD 2017, based on national locations with varying quality of VR data, 2008–16  
The figure shows the degree of consistency between GBD 2016 and GBD 2017 estimates for Level 1 causes at the national level from 2008 to 2016. The diagonal line represents no change from 
GBD 2016 to GBD 2017. Each point represents one country-year, with colours indicating the Level 1 cause grouping (communicable, maternal, neonatal, and nutritional diseases; non-communicable 
diseases; and injuries). Panels indicate whether or not any new VR data between 2008 and 2016 were added for that location for GBD 2017, and whether or not a location has 4-star or 5-star VR 
quality. Points that are outside of the standard 95% prediction interval for a linear regression of 2017 values on 2016 values are annotated (if the same location-cause had multiple points in a time 
series, only the furthest-most point was annotated). The Spearman’s correlation coefficient is noted in the lower right-hand corner of each panel. CSMR=cause-specific mortality rate. GBD=Global 
Burden of Diseases, Injuries, and Risk Factors Study. VR=vital registration.
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Data completeness assessment
Completeness of VR data was assessed by location-year, 
and sources with less than 50% completeness were 
excluded. We multiplied the estimated all-cause mor tality 
for each age-sex-location-year by the cause fraction for the 
corresponding age-sex-location-year to adjust all included 
sources to 100% completeness. VA and VR data availability 
and completeness are shown for each location-year in 
appendix 1 (section 7). To further char acterise the quality 
of data available in each country, the GBD study rated 
each location-year from 1980 to 2017 on a level of 0 to 
5 stars according to methods previously described.18 
Ratings convey an overall measure of the reliability of 
cause of death estimates for each location-year but do not 
directly affect the estimation process.
Cause of death estimation with CODEm
The GBD Cause of Death Ensemble model (CODEm) 
systematically tested and combined results from 
different statistical models according to their out-of-
sample pre dictive validity. Results are incorporated into 
a weighted ensemble model as detailed in appendix 1 
(section 3.1) and below. For GBD 2017, CODEm was 
used to estimate 192 causes of death (appendix 1 
section 7). To predict the level for each cause of death, 
we used CODEm to systematically test a large number 
of functional forms and permutations of covariates.18 
Each resulting model that met the predetermined req-
uirements for regression coefficient significance and 
direction was fit on 70% of the data, holding out 30% for 
cross-validation (appendix 1 section 3.1). Out-of-sample 
pre dictive validity of these models was assessed by use 
of repeated cross-validation tests on the first 15% of the 
held-out data. Various ensemble models with different 
weighting parameters were created from the com-
bination of these models, with the highest weights 
assigned to models with the best out-of-sample pre-
diction error for trends and levels, as detailed in 
appendix 1 (section 7). Model performance of these 
ensembles was assessed against the root-mean squared 
error (RMSE) of the ensemble model predictions of the 
log of the age-specific death rates for a cause, assessed 
with the same 15% of the data. The ensemble model 
performing best was subsequently selected and 
assessed against the other 15% of the data withheld 
from the statistical model building. CODEm was run 
independently by sex for each cause of death. A separate 
model was run for countries with 4-star or greater 
VR systems to avert uncertainty inflation from more 
heterogeneous data. The distribution of RMSE relative 
to cause-specific mortality rates (CSMRs) at Level 2 of 
the GBD hierarchy shows that model performance was 
weakest for causes of death with comparatively low 
mortality rates (figure 2; appendix 2), while models for 
more common causes of death such as stroke, chronic 
obstructive pulmonary disease, and self-harm and 
interpersonal violence generally had low RMSE.
Cause of death estimation with alternative estimation 
strategies
Alternative estimation strategies were used to model a 
subset of causes of death with unique epidemiology, 
large changes in reporting over time, or particularly 
limited data availability, including HIV/AIDS, malaria, 
chronic kidney disease, cirrhosis, liver cancer, men-
ingitis, de mentia, and atrial fibrillation. Alternative 
strategies included prevalence-based models, incidence 
and case fatality models, and sub-cause proportion 
models as described in appendix 1 (section 7). Mortality-
incidence ratio models based on registry data were used 
to estimate mortality from 32 cancers (appendix 1 
section 3.3). Negative-binomial models were used for 
eight causes of death with typically low death counts 
or causes that typically have no deaths in countries 
with a high Socio-demographic Index (SDI), includ-
ing ascariasis, cystic echinococcosis, cysticer cosis, 
diphtheria, iodine deficiency, other intestinal infectious 
diseases, schistosomiasis, and varicella and herpes 
zoster virus. Once underlying cause of death estimates 
and accompanying uncertainty were generated, these 
models were combined with the cause of death 
correction procedure (CoDCorrect) to establish estimates 
consistent with all-cause mortality levels for each age-
sex-year location.
Estimation of fatal discontinuities
Fatal discontinuities are large changes in deaths due to 
unexpected spikes in injuries or epidemics—defined by 
GBD as more than one per million or more than 
Figure 2: Out-of-sample model performance for CODEm models and age-standardised cause-specific 
mortality rate by Level 1 causes
Model performance was defined by the root-mean squared error of the ensemble model predictions of the log of 
the age-specific death rates for a cause with 15% of the data held out from the statistical model building. The figure 
shows the association between the root-mean squared error and the log of the CSMR, aggregated over 1980–2017. 
Each point represents one CODEm model specific for model-specific age ranges and sex. Circles denote models run 
with all locations. Triangles denote models run on only data-rich locations. Colours denote the Level 1 cause 
categories. Open circles and triangles denote models that were run with restricted age groups of less than 30 years. 
CODEm=Cause of Death Ensemble model. CSMR=cause-specific mortality rate. 
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25 deaths—in a specific location-year. We classified 
fatal discontinuities as conflict and terrorism, major 
trans portation accidents, natural disasters, other forms 
of disaster such as large fires or the collapse of large 
buildings, or major outbreaks of infectious diseases. 
Data on fatal discontinuities came from VR data in the 
75 countries with a 4-star or 5-star data quality rat-
ing for the interval of 1980–2017. For the remaining 
120 countries with a rating of 3 stars or lower, we used 
alternative databases (appendix 1 section 7). Cholera 
and meningitis were estimated as fatal discontinuities to 
reduce the risk of underestimation for small-magnitude 
outbreaks caused by the smoothing of VR or VA data 
over time in CODEm. To address lags in reporting and 
publishing of data, we included news reports and other 
supplemental data sources when known gaps existed. 
Further detail about fatal discontinuity estimation is 
presented in appendix 1 (section 3.3).
Pathogen counterfactual analysis
Aetiology-specific mortality was estimated for LRIs and 
diarrhoeal diseases by use of a counterfactual approach 
that relates the frequency of each aetiology in a 
population and the association with that aetiology and 
either LRI or diarrhoea. LRI and diarrhoea were selected 
as initial candidates for this counterfactual analysis 
approach given the large disease burden they represent 
and the broad interest in interventions, mostly vaccine-
based, to reduce their burden.19 We attributed LRI 
deaths to four aetiologies: Haemophilus influenzae 
type B pneumonia, Streptococcus pneumoniae pneum-
ococcal pneumonia, influenza, and respiratory syncyt ial 
virus pneumonia. Diarrhoeal deaths were attribu-
ted to 13 aetiologies: adenovirus, Aeromonas spp, 
Campylobacter spp, Clostridium difficile, cryptospori-
diosis (Cryptosporidium spp), amoebiasis (Entamoeba 
histolytica), typical entero patho genic Escherichia coli, 
enterotoxigenic E coli, noro virus, rotavirus, non-
typhoidal Salmonella spp, shigellosis (Shigella spp), and 
cholera (Vibrio cholerae). The mortality attributable to 
each aetiology is the product of the attributable fraction 
and the mortality due to LRI or diarrhoea. The current 
counterfactual analysis is an extension of work begun in 
GBD 2010, based on the most common pathogens and 
available data. This method allows for less common 
aetiologies to be added in the future.
YLL computation
Years of life lost (YLLs) are a measure of premature death 
calculated as the sum of each death multiplied by the 
standard life expectancy at each age. The standard life 
expectancy was taken from the lowest observed risk of 
death for each five-year age group in all populations 
greater than 5 million. In 2017, GBD 2017 included a 
new demographic assessment of population, fertility, 
migration, and all-cause mortality.14 We used these 
components to generate single calendar-year and single 
age-year estimates of the population using transparent 
and replicable methods.14 This independent assessment 
of the population was subsequently used in the calcula-
tion of YLL rates and age-standardised mortality rates. 
Details of these calculations are available in appendix 1 
(section 4.3).
Decomposition of change in global deaths
Using methods adapted from demographic research 
from Das Gupta,20 we decomposed change in numbers of 
deaths by cause from 2007 to 2017, using three ex-
planatory components: as change occurring from growth 
in the total population; as shifts in population structure 
by age; or as changes in cause-specific mortality rates. 
We calculated the fraction of change in deaths by cause 
from each component using counter factual scenarios, 
changing the level of one factor from 2007 to 2017, with 
all other factors held constant. Since the effect depends 
on the order of entry of the factor, we calculated the 
average of all combinations of the three factors. Thus, the 
change in global deaths due to shifts in population age 
structure could be calculated by comparing the number 
of deaths in 2007 to the number of deaths in 2017, using 
the population age structure from 2017 and holding both 
population size and cause-specific mortality rates at 2007 
levels (appendix 1 section 7).
Uncertainty analysis
Uncertainty in our estimates was attributable to cause-
specific model specifications; varied availability of data by 
age, sex, location, or year; and variability of sample size 
within data sources. We quantified and propagated 
uncertainty into final estimates by calculating uncertainty 
intervals (UIs) for cause-specific estimation components 
based on 1000 draws from the posterior distribu tion 
of cause-specific mortality by age, sex, location, and 
year.21 95% UIs were calculated with the 2·5th and 
97·5th percentiles, and point estimates were calculated 
from the mean of the draws. Changes over time were 
considered statistically significant when the uncertainty 
interval of the percentage change over time did not cross 
zero.
Socio-demographic Index and epidemiological 
transition analysis
The SDI is a value between 0·0 and 1·0 calculated from 
the geometric mean of three rescaled components: total 
fertility rate under 25 years (TFRU25), lag-distributed 
income per capita (LDI), and average educational 
attainment in the population older than 15 years.22 
Because the total fertility rate—used in the calculation 
of SDI for GBD 2016—has a U-shaped association at 
the highest levels of development, for GBD 2017 we 
recomputed the SDI using TFRU25 only, an age range for 
which the association with development is clearest.14 We 
used a generalised additive model with a Loess smoother 
on SDI to estimate the association between SDI and each 
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All-age deaths (thousands) Age-standardised death rate 
(per 100 000)
All-age YLLs (thousands) Age-standardised YLL rate 
(per 100 000)
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
All causes 55 945·7 
(55 356·4 to 
56 516·7)
9·3% 
(8·2 to 10·2)*
737·7 
(729·9 to 745·4)
–14·2% 
(–15·0 to –13·5)*
1 646 249·6 
(1 622 870·6 to 
1 673 178·4)
–9·0% 
(–10·1 to –7·6)*
21 926·4 
(21 601·1 to 
22 314·9)
–22·2% 
(–23·2 to –21·0)*
Communicable, maternal, 
neonatal, and nutritional 
diseases
10 389·9 
(10 004·0 to 
10 975·9)
–22·2% 
(–24·0 to –20·0)*
143·8 
(138·4 to 151·6)
–31·8% 
(–33·3 to –30·1)*
578 416·6 
(558 815·0 to 
600 759·1)
–30·4% 
(–32·4 to –28·2)*
8280·6 
(8005·4 to 
8602·8)
–35·4% 
(–37·3 to –33·4)*
HIV/AIDS and sexually 
transmitted infections
1073·6 
(983·3 to 
1182·4)
–47·7% 
(–50·0 to –45·1)*
13·9 
(12·6 to 15·5)
–53·6% 
(–55·8 to –51·0)*
60 550·2 
(53 533·7 to 
69 156·3)
–47·3% 
(–50·2 to 
–44·0)*
806·4 
(703·1 to 
936·7)
–52·1% 
(–55·2 to –48·6)*
HIV/AIDS 954·5 
(907·3 to 
1009·7)
–50·3% 
(–52·1 to –48·3)*
12·1 
(11·5 to 12·9)
–56·5% 
(–58·0 to –54·7)*
50 497·1 
(47 658·0 to 
53 595·8)
–51·2% 
(–52·9 to –49·2)*
655·1 
(617·5 to 696·4)
–56·6% 
(–58·1 to –54·8)*
HIV/AIDS and 
drug-susceptible 
tuberculosis co-infection
194·6 
(137·7 to 253·0)
–55·4% 
(–58·4 to –51·6)*
2·5 
(1·8 to 3·2)
–61·1% 
(–63·7 to –57·7)*
10 664·8 
(7613·4 to 13 757·1)
–55·6% 
(–58·7 to –51·7)*
140·0 
(100·2 to 180·0)
–60·5% 
(–63·1 to –57·0)*
HIV/AIDS and multidrug-
resistant tuberculosis 
without extensive drug 
resistance co-infection
22·6 
(13·4 to 34·5)
–52·2% 
(–66·4 to –33·2)*
0·3 
(0·2 to 0·4)
–58·1% 
(–70·5 to –41·5)*
1247·8 
(746·6 to 1906·7)
–51·7% 
(–65·7 to –33·2)*
16·4 
(9·8 to 25·1)
–56·8% 
(–69·3 to –40·4)*
HIV/AIDS and extensively 
drug-resistant tuberculosis 
co-infection
1·2 
(0·8 to 1·8)
–8·3% 
(–26·8 to 14·7)
0·0 
(0·0 to 0·0)
–20·3% 
(–36·4 to –0·2)*
62·7 
(38·3 to 92·9)
–10·5% 
(–28·4 to 11·5)
0·8 
(0·5 to 1·2)
–21·0% 
(–36·7 to –1·4)*
HIV/AIDS resulting in other 
diseases
736·0 
(659·5 to 817·7)
–48·7% 
(–51·1 to –45·9)*
9·3 
(8·4 to 10·4)
–55·1% 
(–57·2 to –52·6)*
38 521·8 
(34 381·3 to 
43 095·5)
–49·8% 
(–52·3 to –46·9)*
497·9 
(444·2 to 558·4)
–55·4% 
(–57·6 to –52·8)*
Sexually transmitted 
infections excluding HIV
119·1 
(50·8 to 220·4)
–10·8% 
(–18·4 to –2·5)*
1·8 
(0·7 to 3·3)
–14·4% 
(–21·5 to –6·6)*
10 053·1 
(4057·0 to 
18 915·2)
–11·4% 
(–19·0 to –3·2)*
151·3 
(60·6 to 285·3)
–14·4% 
(–21·8 to –6·6)*
Syphilis 113·5 
(45·2 to 214·5)
–11·3% 
(–19·1 to –2·8)*
1·7 
(0·7 to 3·2)
–14·3% 
(–21·8 to –6·4)*
9836·1 
(3848·5 to 
18 676·4)
–11·5% 
(–19·3 to –3·1)*
148·6 
(58·0 to 282·3)
–14·3% 
(–21·8 to –6·2)*
Chlamydial infection 1·1 
(0·9 to 1·2)
2·5% 
(–4·5 to 11·3)
0·0 
(0·0 to 0·0)
–15·2% 
(–21·0 to –8·4)*
40·5 
(32·6 to 45·0)
–5·5% 
(–12·2 to 2·5)
0·5 
(0·4 to 0·6)
–17·9% 
(–23·7 to –11·0)*
Gonococcal infection 3·0 
(2·4 to 3·3)
3·7% 
(–3·4 to 12·5)
0·0 
(0·0 to 0·0)
–14·9% 
(–20·8 to –8·2)*
112·8 
(90·2 to 124·9)
–3·8% 
(–10·7 to 4·3)
1·4 
(1·1 to 1·6)
–17·4% 
(–23·5 to –10·7)*
Other sexually transmitted 
infections
1·5 
(1·2 to 1·7)
0·2% 
(–6·4 to 8·3)
0·0 
(0·0 to 0·0)
–15·9% 
(–21·6 to –9·5)*
63·6 
(51·0 to 70·7)
–6·2% 
(–12·7 to 1·1)
0·8 
(0·6 to 0·9)
–18·2% 
(–23·9 to –11·7)*
Respiratory infections and 
tuberculosis
3752·3 
(3629·4 to 
3889·3)
–8·0% 
(–10·3 to –5·5)*
50·5 
(48·8 to 52·3)
–24·5% 
(–26·4 to –22·6)*
148 233·5 
(141 335·1 to 
155 291·4)
–24·7% 
(–27·4 to –21·7)*
2056·0 
(1956·3 to 
2160·7)
–32·8% 
(–35·4 to –30·0)*
Tuberculosis 1183·7 
(1129·8 to 
1245·3)
–14·9% 
(–18·2 to –10·3)*
14·9 
(14·3 to 15·7)
–31·4% 
(–34·1 to –27·6)*
41 876·9 
(39 972·4 to 
44 120·5)
–21·2% 
(–24·4 to –17·4)*
533·4 
(509·1 to 562·6)
–33·3% 
(–35·9 to –30·0)*
Drug-susceptible 
tuberculosis
1044·1 
(951·6 to 
1129·2)
–15·5% 
(–22·3 to –8·6)*
13·2 
(12·0 to 14·2)
–31·9% 
(–37·3 to –26·4)*
36 932·5 
(33 846·8 to 
39 919·1)
–21·9% 
(–27·8 to –16·0)*
470·7 
(431·3 to 508·4)
–33·8% 
(–38·7 to –29·0)*
Multidrug-resistant 
tuberculosis without 
extensive drug resistance
126·9 
(70·1 to 202·2)
–11·6% 
(–47·4 to 38·1)
1·6 
(0·9 to 2·5)
–28·6% 
(–57·4 to 11·4)
4505·1 
(2582·5 to 6984·6)
–17·6% 
(–49·4 to 26·5)
57·2 
(33·0 to 88·4)
–30·2% 
(–56·9 to 6·6)
Extensively drug-resistant 
tuberculosis
12·6 
(8·6 to 18·0)
14·0% 
(–18·7 to 58·7)
0·2 
(0·1 to 0·2)
–7·7% 
(–34·1 to 28·8)
439·2 
(306·2 to 616·5)
5·5% 
(–23·2 to 44·9)
5·5 
(3·8 to 7·7)
–11·1% 
(–35·2 to 22·1)
Lower respiratory infections 2558·6 
(2442·2 to 
2655·4)
–4·3% 
(–6·9 to –1·5)*
35·4 
(33·8 to 36·8)
–21·1% 
(–23·2 to –18·9)*
105 834·5 
(99 746·4 to 
111 767·8)
–25·9% 
(–29·2 to –22·2)*
1515·1 
(1424·8 to 
1602·2)
–32·6% 
(–35·7 to –29·2)*
Upper respiratory infections 9·1 
(6·1 to 12·4)
–30·5% 
(–41·0 to –14·5)*
0·1 
(0·1 to 0·2)
–42·1% 
(–49·6 to –29·9)*
477·3 
(247·3 to 730·5)
–33·2% 
(–44·1 to –12·9)*
6·9 
(3·5 to 10·6)
–38·6% 
(–48·3 to –19·4)*
Otitis media 0·9 
(0·7 to 1·5)
–41·4% 
(–51·6 to –28·4)*
0·0 
(0·0 to 0·0)
–50·4% 
(–58·8 to –39·9)*
44·8 
(31·2 to 72·1)
–49·4% 
(–59·9 to –35·5)*
0·6 
(0·4 to 1·0)
–54·5% 
(–64·1 to –41·8)*
(Table 1 continues on next page)
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All-age deaths (thousands) Age-standardised death rate 
(per 100 000)
All-age YLLs (thousands) Age-standardised YLL rate 
(per 100 000)
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
(Continued from previous page)
Enteric infections 1766·0 
(1398·0 to 
2386·0)
–17·2% 
(–24·6 to –8·2)*
24·4 
(19·5 to 32·4)
–29·9% 
(–34·9 to –23·1)*
84 625·5 
(73 770·6 to 
100 720·2)
–30·6% 
(–36·3 to –23·7)*
1208·6 
(1064·1 to 
1424·7)
–36·6% 
(–41·8 to –30·7)*
Diarrhoeal diseases 1569·6 
(1176·0 to 
2193·0)
–16·6% 
(–25·3 to –6·7)*
21·6 
(16·4 to 29·7)
–30·2% 
(–36·1 to –22·7)*
70 574·3 
(60 421·1 to 
86 165·2)
–32·0% 
(–38·6 to –23·9)*
1009·1 
(870·5 to 
1211·0)
–38·1% 
(–43·9 to –31·3)*
Typhoid and paratyphoid 135·9 
(76·9 to 218·9)
–22·3% 
(–27·3 to –18·1)*
1·9 
(1·1 to 3·0)
–27·8% 
(–32·8 to –23·9)*
9686·1 
(5484·9 to 
15 746·2)
–23·8% 
(–29·3 to –19·4)*
136·3 
(77·0 to 220·9)
–28·7% 
(–34·0 to –24·4)*
Typhoid fever 116·8 
(65·4 to 187·7)
–23·7% 
(–29·0 to –19·3)*
1·6 
(0·9 to 2·6)
–29·1% 
(–34·1 to –25·0)*
8331·7 
(4632·5 to 
13 419·2)
–25·3% 
(–31·0 to –20·8)*
117·3 
(65·5 to 188·5)
–30·1% 
(–35·6 to –25·7)*
Paratyphoid fever 19·1 
(8·7 to 37·3)
–12·7% 
(–20·1 to –4·2)*
0·3 
(0·1 to 0·5)
–18·9% 
(–26·1 to –10·8)*
1354·4 
(622·3 to 2620·2)
–13·2% 
(–21·3 to –3·8)*
19·0 
(8·8 to 36·6)
–18·6% 
(–26·5 to –9·7)*
Invasive non-typhoidal 
salmonella
59·1 
(33·3 to 98·1)
–17·9% 
(–25·1 to –8·7)*
0·8 
(0·5 to 1·4)
–24·8% 
(–31·9 to –15·6)*
4260·8 
(2382·0 to 7378·6)
–17·2% 
(–25·7 to –6·8)*
61·6 
(34·7 to 107·6)
–22·6% 
(–30·7 to –12·5)*
Other intestinal infectious 
diseases
1·4 
(1·0 to 2·2)
–39·7% 
(–67·1 to 9·7)
0·0 
(0·0 to 0·0)
–44·7% 
(–70·1 to 2·3)
104·4 
(67·8 to 170·7)
–43·6% 
(–71·6 to 11·9)
1·5 
(1·0 to 2·5)
–46·9% 
(–73·7 to 6·3)
Neglected tropical diseases 
and malaria
720·1 
(530·7 to 
938·8)
–29·0% 
(–37·3 to –19·3)*
10·1 
(7·5 to 13·2)
–36·1% 
(–43·7 to –27·3)*
48 656·2 
(35 574·6 to 
64 934·2)
–33·7% 
(–42·4 to –23·7)*
699·9 
(508·0 to 
933·6)
–38·6% 
(–46·7 to –29·2)*
Malaria 619·8 
(440·1 to 839·5)
–30·8% 
(–39·4 to –20·8)*
8·7 
(6·1 to 11·9)
–37·3% 
(–45·4 to –27·9)*
43 546·6 
(29 966·3 to 
59 772·4)
–34·5% 
(–43·8 to –23·6)*
629·4 
(432·6 to 858·7)
–39·2% 
(–48·2 to –28·8)*
Chagas disease 7·9 
(7·5 to 8·6)
3·8% 
(–1·6 to 12·9)
0·1 
(0·1 to 0·1)
–21·1% 
(–25·2 to –14·3)*
174·9 
(166·1 to 193·5)
–4·2% 
(–9·0 to 4·8)
2·2 
(2·0 to 2·4)
–25·1% 
(–28·9 to –18·1)*
Leishmaniasis 7·5 
(0·0 to 34·5)
–64·8% 
(–96·8 to –44·5)*
0·1 
(0·0 to 0·5)
–67·8% 
(–97·5 to –50·3)*
509·8 
(0·3 to 2440·2)
–63·8% 
(–92·1 to –39·7)*
7·2 
(0·0 to 34·6)
–66·2% 
(–93·2 to –43·8)*
Visceral leishmaniasis 7·5 
(0·0 to 34·5)
–64·8% 
(–96·8 to –44·5)*
0·1 
(0·0 to 0·5)
–67·8% 
(–97·5 to –50·3)*
509·8 
(0·3 to 2440·2)
–63·8% 
(–92·1 to –39·7)*
7·2 
(0·0 to 34·6)
–66·2% 
(–93·2 to –43·8)*
African trypanosomiasis 1·4 
(0·3 to 4·9)
–80·7% 
(–95·6 to –27·8)*
0·0 
(0·0 to 0·1)
–82·8% 
(–96·0 to –34·3)*
77·6 
(15·0 to 283·6)
–80·8% 
(–95·6 to –27·2)*
1·0 
(0·2 to 3·8)
–82·3% 
(–96·0 to –33·6)*
Schistosomiasis 8·8 
(8·0 to 9·8)
–12·3% 
(–17·6 to –6·4)*
0·1 
(0·1 to 0·1)
–28·5% 
(–32·7 to –23·7)*
342·3 
(305·3 to 384·3)
–15·6% 
(–21·9 to –8·8)*
4·4 
(3·9 to 5·0)
–27·4% 
(–32·9 to –21·4)*
Cysticercosis 0·7 
(0·5 to 1·0)
–15·9% 
(–42·7 to 23·3)
0·0 
(0·0 to 0·0)
–27·3% 
(–50·5 to 5·3)
39·6 
(26·9 to 55·0)
–20·5% 
(–46·9 to 18·2)
0·5 
(0·4 to 0·7)
–28·9% 
(–52·5 to 4·8)
Cystic echinococcosis 1·2 
(0·9 to 1·5)
–30·0% 
(–52·1 to –1·3)*
0·0 
(0·0 to 0·0)
–41·9% 
(–59·8 to –19·0)*
52·0 
(38·1 to 68·0)
–38·8% 
(–56·8 to –12·9)*
0·7 
(0·5 to 0·9)
–46·4% 
(–62·0 to –24·1)*
Dengue 40·5 
(17·6 to 49·8)
65·5% 
(21·7 to 99·7)*
0·5 
(0·2 to 0·7)
40·7% 
(3·6 to 69·7)*
1902·9 
(716·6 to 2312·9)
32·0% 
(–1·8 to 61·2)
26·1 
(9·8 to 31·7)
18·2% 
(–12·0 to 45·0)
Yellow fever 4·8 
(1·0 to 13·8)
–16·6% 
(–28·7 to –2·0)*
0·1 
(0·0 to 0·2)
–23·3% 
(–34·4 to –9·6)*
313·9 
(67·2 to 900·2)
–16·0% 
(–28·9 to 0·0)
4·3 
(0·9 to 12·4)
–21·3% 
(–33·6 to –5·8)*
Rabies 11·7 
(9·3 to 14·7)
–48·1% 
(–58·8 to –37·3)*
0·2 
(0·1 to 0·2)
–54·8% 
(–63·8 to –45·0)*
633·7 
(504·4 to 836·4)
–51·5% 
(–61·3 to –38·9)*
8·6 
(6·8 to 11·5)
–56·2% 
(–65·1 to –44·3)*
Intestinal nematode 
infections
3·2 
(2·5 to 4·1)
–43·1% 
(–56·1 to –25·0)*
0·0 
(0·0 to 0·1)
–47·2% 
(–59·5 to –30·1)*
257·1 
(194·1 to 336·3)
–44·1% 
(–57·6 to –25·0)*
3·8 
(2·9 to 5·0)
–47·6% 
(–60·4 to –29·6)*
Ascariasis 3·2 
(2·5 to 4·1)
–43·1% 
(–56·1 to –25·0)*
0·0 
(0·0 to 0·1)
–47·2% 
(–59·5 to –30·1)*
257·1 
(194·1 to 336·3)
–44·1% 
(–57·6 to –25·0)*
3·8 
(2·9 to 5·0)
–47·6% 
(–60·4 to –29·6)*
Ebola virus disease 0·0 
(0·0 to 0·0)
–98·2% 
(–98·4 to –98·0)*
0·0 
(0·0 to 0·0)
–98·4% 
(–98·6 to –98·2)*
0·5 
(0·5 to 0·5)
–98·1% 
(–98·3 to –97·9)*
0·0 
(0·0 to 0·0)
–98·2% 
(–98·4 to –98·0)*
Zika virus disease 0·0 
(0·0 to 0·1)
·· 0·0 
(0·0 to 0·0)
·· 1·0 
(0·2 to 3·4)
·· 0·0 
(0·0 to 0·0)
··
Other neglected tropical 
diseases
12·6 
(8·0 to 36·3)
8·1% 
(–8·1 to 28·2)
0·2 
(0·1 to 0·5)
–3·7% 
(–18·3 to 13·9)
804·3 
(442·8 to 2696·6)
3·9% 
(–16·3 to 29·4)
11·6 
(6·3 to 39·6)
–3·5% 
(–22·2 to 20·7)
(Table 1 continues on next page)
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All-age deaths (thousands) Age-standardised death rate 
(per 100 000)
All-age YLLs (thousands) Age-standardised YLL rate 
(per 100 000)
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
(Continued from previous page)
Other infectious diseases 830·5 
(732·2 to 
947·8)
–25·9% 
(–32·4 to –18·8)*
11·6 
(10·1 to 13·3)
–33·8% 
(–39·3 to –27·4)*
53 008·6 
(44 786·0 to 
63 000·4)
–33·0% 
(–39·6 to –25·1)*
762·8 
(640·5 to 911·5)
–37·9% 
(–44·0 to –30·5)*
Meningitis 288·0 
(254·3 to 333·2)
–20·1% 
(–26·0 to –11·0)*
4·0 
(3·6 to 4·6)
–27·8% 
(–33·1 to –19·3)*
19 436·9 
(16 935·1 to 
22 335·8)
–25·2% 
(–31·5 to –15·7)*
280·5 
(243·6 to 323·2)
–30·2% 
(–36·3 to –21·4)*
Pneumococcal meningitis 42·1 
(36·6 to 49·4)
–13·4% 
(–20·6 to –2·3)*
0·6 
(0·5 to 0·7)
–22·4% 
(–28·9 to –12·4)*
2751·8 
(2325·8 to 3276·5)
–18·5% 
(–26·8 to –6·5)*
39·6 
(33·4 to 47·0)
–24·2% 
(–32·1 to –12·8)*
H influenzae type B 
meningitis
75·7 
(66·7 to 92·0)
–33·7% 
(–39·6 to –26·0)*
1·1 
(0·9 to 1·3)
–40·6% 
(–45·8 to –33·9)*
4907·3 
(4232·2 to 5813·6)
–40·4% 
(–46·1 to –33·0)*
70·5 
(60·6 to 83·9)
–44·7% 
(–50·1 to –37·7)*
Meningococcal infection 30·0 
(25·7 to 35·7)
–31·5% 
(–37·4 to –22·8)*
0·4 
(0·4 to 0·5)
–37·1% 
(–42·6 to –29·2)*
2180·3 
(1819·8 to 2614·5)
–34·9% 
(–41·4 to –26·4)*
31·9 
(26·5 to 38·4)
–38·8% 
(–45·0 to –30·5)*
Other meningitis 140·3 
(121·4 to 161·8)
–8·9% 
(–15·4 to 1·4)
2·0 
(1·7 to 2·3)
–17·3% 
(–23·4 to –7·5)*
9597·5 
(8195·6 to 
11 118·5)
–12·8% 
(–20·4 to –0·7)*
138·5 
(118·3 to 160·5)
–18·4% 
(–25·7 to –7·4)*
Encephalitis 92·4 
(83·1 to 107·9)
0·0% 
(–14·2 to 16·2)
1·2 
(1·1 to 1·4)
–14·3% 
(–26·5 to –0·9)*
4588·2 
(4059·5 to 5230·7)
–12·1% 
(–28·1 to 4·5)
64·1 
(56·6 to 72·4)
–20·1% 
(–35·0 to –5·0)*
Diphtheria 3·6 
(2·2 to 6·1)
–23·9% 
(–55·6 to 36·4)
0·1 
(0·0 to 0·1)
–28·6% 
(–58·8 to 29·2)
298·7 
(181·8 to 510·0)
–23·9% 
(–56·7 to 38·7)
4·4 
(2·7 to 7·6)
–28·3% 
(–59·5 to 31·4)
Whooping cough 91·8 
(45·9 to 163·2)
–23·3% 
(–54·8 to 35·6)
1·4 
(0·7 to 2·4)
–27·1% 
(–57·1 to 28·8)
7879·2 
(3938·1 to 
14 010·3)
–23·3% 
(–54·8 to 35·4)
117·9 
(58·9 to 209·6)
–27·1% 
(–57·0 to 28·8)
Tetanus 38·1 
(25·9 to 48·8)
–54·9% 
(–65·9 to –39·1)*
0·5 
(0·4 to 0·7)
–59·6% 
(–69·3 to –45·0)*
2447·7 
(1734·9 to 3199·0)
–59·3% 
(–69·9 to –43·5)*
35·1 
(25·0 to 46·3)
–62·1% 
(–72·1 to –47·0)*
Measles 95·3 
(34·5 to 205·2)
–57·0% 
(–61·9 to –51·9)*
1·4 
(0·5 to 3·1)
–59·3% 
(–64·0 to –54·4)*
8105·1 
(2935·7 to 
17 469·0)
–56·9% 
(–61·8 to –51·8)*
120·8 
(43·7 to 260·4)
–59·2% 
(–63·9 to –54·3)*
Varicella and herpes zoster 15·6 
(14·4 to 17·3)
–16·4% 
(–22·9 to –9·5)*
0·2 
(0·2 to 0·2)
–29·2% 
(–34·7 to –23·4)*
833·0 
(742·3 to 938·1)
–22·5% 
(–31·4 to –13·2)*
12·1 
(10·7 to 13·6)
–28·4% 
(–36·6 to –19·4)*
Acute hepatitis 126·4 
(94·5 to 143·7)
–9·8% 
(–15·5 to –2·3)*
1·6 
(1·2 to 1·9)
–24·5% 
(–29·2 to –18·4)*
5478·4 
(4040·3 to 6330·0)
–21·7% 
(–27·7 to –14·4)*
72·3 
(52·9 to 83·9)
–31·2% 
(–36·5 to –24·9)*
Acute hepatitis A 18·6 
(13·6 to 23·8)
–33·1% 
(–41·9 to –22·5)*
0·3 
(0·2 to 0·3)
–38·7% 
(–46·8 to –28·6)*
1286·7 
(935·2 to 1633·7)
–36·0% 
(–45·1 to –24·3)*
18·0 
(13·0 to 22·9)
–40·7% 
(–49·1 to –29·0)*
Acute hepatitis B 89·6 
(66·1 to 102·5)
–0·8% 
(–8·4 to 8·5)
1·1 
(0·8 to 1·3)
–19·6% 
(–25·4 to –12·4)*
3262·4 
(2367·8 to 3819·1)
–12·2% 
(–19·7 to –2·7)*
41·8 
(30·1 to 49·3)
–25·6% 
(–31·9 to –17·5)*
Acute hepatitis C 3·5 
(1·9 to 6·0)
–23·7% 
(–35·9 to –9·4)*
0·0 
(0·0 to 0·1)
–32·1% 
(–42·4 to –19·6)*
219·7 
(120·1 to 371·3)
–31·0% 
(–43·3 to –15·3)*
3·2 
(1·8 to 5·4)
–35·5% 
(–47·2 to –20·7)*
Acute hepatitis E 14·7 
(10·4 to 18·5)
–15·8% 
(–27·2 to –3·1)*
0·2 
(0·1 to 0·2)
–25·8% 
(–35·3 to –15·6)*
709·6 
(489·6 to 903·9)
–25·5% 
(–35·2 to –14·5)*
9·3 
(6·4 to 11·8)
–31·9% 
(–40·6 to –22·0)*
Other unspecified infectious 
diseases
79·3 
(59·9 to 85·1)
1·6% 
(–3·1 to 7·9)
1·1 
(0·8 to 1·2)
–13·4% 
(–17·5 to –8·1)*
3941·3 
(2831·7 to 4325·8)
–10·2% 
(–16·2 to –2·4)*
55·6 
(39·6 to 61·3)
–17·9% 
(–23·6 to –10·6)*
Maternal and neonatal 
disorders
1977·4 
(1890·1 to 
2060·6)
–24·1% 
(–26·9 to –21·0)*
29·5 
(28·2 to 30·8)
–26·6% 
(–29·3 to –23·5)*
167 684·6 
(160 060·7 to 
174 918·2)
–24·2% 
(–27·1 to –20·9)*
2518·2 
(2403·8 to 
2627·1)
–26·5% 
(–29·3 to –23·3)*
Maternal disorders 193·6 
(179·9 to 209·6)
–24·0% 
(–28·4 to –19·5)*
2·5 
(2·3 to 2·7)
–30·7% 
(–34·8 to –26·6)*
10 993·1 
(10 198·9 to 
11 928·5)
–25·3% 
(–29·7 to –20·9)*
140·9 
(130·8 to 153·0)
–31·5% 
(–35·5 to –27·5)*
Maternal haemorrhage 38·5 
(33·2 to 45·2)
–52·1% 
(–59·0 to –44·2)*
0·5 
(0·4 to 0·6)
–56·4% 
(–62·7 to –49·3)*
2173·8 
(1859·7 to 2552·5)
–53·0% 
(–60·1 to –45·0)*
27·8 
(23·8 to 32·7)
–57·1% 
(–63·6 to –49·7)*
Maternal sepsis and other 
pregnancy-related 
infections
21·2 
(18·2 to 25·0)
–27·1% 
(–38·8 to –15·1)*
0·3 
(0·2 to 0·3)
–33·5% 
(–44·2 to –22·6)*
1198·0 
(1022·8 to 1420·8)
–28·9% 
(–41·1 to –16·2)*
15·4 
(13·1 to 18·3)
–34·5% 
(–45·4 to –22·5)*
Maternal hypertensive 
disorders
29·4 
(25·4 to 34·5)
–5·5% 
(–20·7 to 11·2)
0·4 
(0·3 to 0·4)
–13·0% 
(–27·3 to 2·6)
1729·6 
(1487·6 to 2033·2)
–6·6% 
(–22·1 to 10·2)
22·3 
(19·2 to 26·4)
–13·6% 
(–28·1 to 2·0)
Maternal obstructed labour 
and uterine rupture
13·0 
(10·2 to 16·8)
–17·7% 
(–35·9 to 2·9)
0·2 
(0·1 to 0·2)
–25·2% 
(–41·0 to –6·3)*
720·9 
(565·5 to 946·4)
–18·9% 
(–37·6 to 1·9)
9·2 
(7·2 to 12·1)
–25·8% 
(–42·9 to –6·9)*
(Table 1 continues on next page)
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(per 100 000)
All-age YLLs (thousands) Age-standardised YLL rate 
(per 100 000)
2017 Percentage 
change, 2007–17
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change, 2007–17
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(Continued from previous page)
Maternal abortive outcome 17·4 
(14·7 to 20·8)
–7·0% 
(–22·3 to 10·1)
0·2 
(0·2 to 0·3)
–15·7% 
(–29·3 to –0·4)*
963·4 
(807·6 to 1161·1)
–8·9% 
(–24·2 to 8·7)
12·3 
(10·3 to 14·9)
–16·8% 
(–30·7 to –0·5)*
Ectopic pregnancy 10·2 
(7·1 to 15·2)
–11·6% 
(–41·4 to 27·9)
0·1 
(0·1 to 0·2)
–19·2% 
(–46·2 to 16·8)
590·6 
(409·0 to 881·4)
–13·3% 
(–43·8 to 26·9)
7·6 
(5·3 to 11·4)
–20·3% 
(–48·1 to 17·0)
Indirect maternal deaths 34·1 
(30·0 to 38·7)
–4·1% 
(–16·7 to 8·5)
0·4 
(0·4 to 0·5)
–12·5% 
(–24·0 to –1·0)*
1934·4 
(1694·2 to 2216·7)
–6·1% 
(–19·2 to 6·8)
24·8 
(21·7 to 28·5)
–13·9% 
(–25·8 to –2·3)*
Late maternal deaths 3·4 
(2·6 to 4·3)
–0·9% 
(–7·0 to 5·5)
0·0 
(0·0 to 0·1)
–9·5% 
(–14·7 to –4·0)*
194·7 
(152·2 to 251·4)
–2·0% 
(–8·2 to 4·1)
2·5 
(2·0 to 3·2)
–10·1% 
(–15·4 to –4·5)*
Maternal deaths 
aggravated by HIV/AIDS
1·6 
(1·0 to 2·1)
–23·9% 
(–31·0 to –16·0)*
0·0 
(0·0 to 0·0)
–32·1% 
(–38·4 to –25·2)*
84·4 
(53·0 to 113·8)
–26·7% 
(–33·6 to –19·2)*
1·1 
(0·7 to 1·4)
–34·2% 
(–40·6 to –27·5)*
Other maternal disorders 24·8 
(20·8 to 29·8)
–8·5% 
(–24·7 to 11·2)
0·3 
(0·3 to 0·4)
–16·5% 
(–31·2 to 1·5)
1403·1 
(1159·5 to 1690·3)
–9·8% 
(–26·7 to 10·8)
18·0 
(14·9 to 21·7)
–17·2% 
(–32·9 to 1·2)
Neonatal disorders 1783·8 
(1698·5 to 
1864·7)
–24·1% 
(–27·2 to –20·6)*
27·1 
(25·8 to 28·3)
–26·2% 
(–29·1 to –22·7)*
156 691·6 
(149 207·2 to 
163 802·2)
–24·1% 
(–27·2 to –20·6)*
2377·2 
(2263·7 to 
2485·1)
–26·2% 
(–29·1 to –22·7)*
Neonatal preterm birth 649·4 
(605·4 to 721·3)
–26·2% 
(–31·3 to –21·5)*
9·9 
(9·2 to 10·9)
–28·1% 
(–33·2 to –23·6)*
57 052·0 
(53 182·3 to 
63 367·1)
–26·2% 
(–31·3 to –21·5)*
865·6 
(806·9 to 961·5)
–28·1% 
(–33·2 to –23·6)*
Neonatal encephalopathy 
due to birth asphyxia and 
trauma
533·3 
(476·9 to 
580·3)
–24·5% 
(–30·2 to –18·0)*
8·1 
(7·2 to 8·8)
–26·5% 
(–32·0 to –20·2)*
46 845·9 
(41 894·1 to 
50 985·7)
–24·5% 
(–30·2 to –18·0)*
710·8 
(635·7 to 773·7)
–26·5% 
(–32·0 to –20·2)*
Neonatal sepsis and other 
neonatal infections
203·0 
(178·7 to 267·1)
–11·9% 
(–20·5 to –1·7)*
3·1 
(2·7 to 4·1)
–14·4% 
(–22·7 to –4·4)*
17 830·7 
(15 692·9 to 
23 459·0)
–11·9% 
(–20·5 to –1·7)*
270·4 
(238·0 to 355·8)
–14·4% 
(–22·7 to –4·4)*
Haemolytic disease and 
other neonatal jaundice
49·1 
(42·9 to 55·9)
–37·5% 
(–45·3 to –28·2)*
0·7 
(0·7 to 0·8)
–39·3% 
(–46·8 to –30·2)*
4309·1 
(3771·2 to 4914·0)
–37·5% 
(–45·3 to –28·2)*
65·4 
(57·2 to 74·5)
–39·3% 
(–46·8 to –30·2)*
Other neonatal disorders 349·0 
(294·9 to 382·3)
–23·6% 
(–29·8 to –15·5)*
5·3 
(4·5 to 5·8)
–25·7% 
(–31·7 to –17·8)*
30 654·0 
(25 899·7 to 
33 578·7)
–23·6% 
(–29·8 to –15·5)*
465·0 
(392·9 to 509·4)
–25·7% 
(–31·7 to –17·8)*
Nutritional deficiencies 270·0 
(249·3 to 
295·5)
–23·9% 
(–29·2 to –15·7)*
3·8 
(3·5 to 4·2)
–33·6% 
(–38·1 to –26·5)*
15 658·0 
(14 051·5 to 
17 506·6)
–34·7% 
(–40·5 to –26·1)*
228·7 
(204·9 to 
255·9)
–39·4% 
(–44·8 to –31·4)*
Protein-energy malnutrition 231·8 
(212·4 to 254·2)
–26·1% 
(–31·7 to –17·9)*
3·3 
(3·0 to 3·7)
–34·6% 
(–39·4 to –27·5)*
14 405·4 
(12 873·5 to 
16 128·0)
–35·1% 
(–41·1 to –26·7)*
211·8 
(189·0 to 237·3)
–39·4% 
(–45·0 to –31·6)*
Other nutritional deficiencies 38·2 
(33·7 to 44·6)
–7·2% 
(–14·6 to 3·1)
0·5 
(0·4 to 0·6)
–25·8% 
(–31·7 to –17·5)*
1252·7 
(1087·5 to 1435·2)
–29·2% 
(–36·9 to –19·7)*
16·9 
(14·6 to 19·5)
–38·6% 
(–45·4 to –30·4)*
Non-communicable diseases 41 071·1 
(40 470·9 to 
41 548·9)
22·7% 
(21·5 to 23·9)*
536·1 
(528·4 to 542·2)
–7·9% 
(–8·8 to –7·0)*
872 601·8 
(859 538·6 to 
884 787·7)
13·6% 
(12·2 to 14·9)*
11 097·4 
(10 928·6 to 
11 253·8)
–9·6% 
(–10·7 to –8·6)*
Neoplasms 9556·2 
(9395·7 to 
9692·3)
25·4% 
(23·9 to 27·0)*
121·2 
(119·1 to 122·9)
–4·4% 
(–5·6 to –3·3)*
225 738·1 
(221 608·8 to 
229 322·4)
19·6% 
(17·8 to 21·4)*
2803·4 
(2751·5 to 
2848·8)
–5·6% 
(–7·0 to –4·1)*
Lip and oral cavity cancer 193·7 
(184·7 to 201·6)
35·6% 
(29·5 to 40·8)*
2·4 
(2·3 to 2·5)
4·0% 
(–0·6 to 8·0)
5090·6 
(4819·5 to 5328·3)
30·5% 
(23·8 to 36·4)*
62·2 
(58·9 to 65·1)
3·0% 
(–2·3 to 7·6)
Nasopharynx cancer 69·5 
(66·9 to 72·3)
24·4% 
(20·0 to 28·8)*
0·9 
(0·8 to 0·9)
–3·0% 
(–6·4 to 0·4)
2034·5 
(1954·7 to 2117·4)
18·3% 
(13·9 to 23·1)*
24·8 
(23·8 to 25·8)
–5·0% 
(–8·5 to –1·3)*
Other pharynx cancer 117·4 
(102·1 to 124·5)
40·4% 
(29·7 to 48·4)*
1·4 
(1·3 to 1·5)
7·9% 
(–0·3 to 14·0)
3204·2 
(2766·3 to 3405·1)
36·0% 
(25·4 to 44·2)*
38·9 
(33·5 to 41·3)
6·5% 
(–1·7 to 12·8)
Oesophageal cancer 436·0 
(425·0 to 447·6)
13·0% 
(9·9 to 16·3)*
5·5 
(5·3 to 5·6)
–14·5% 
(–16·9 to –12·0)*
9647·5 
(9410·7 to 9903·5)
8·9% 
(5·8 to 12·2)*
118·3 
(115·4 to 121·4)
–16·2% 
(–18·6 to –13·7)*
Stomach cancer 865·0 
(848·3 to 884·7)
9·4% 
(7·1 to 12·1)*
11·0 
(10·8 to 11·2)
–17·1% 
(–18·8 to –15·1)*
18 782·0 
(18 409·7 to 
19 207·7)
4·8% 
(2·4 to 7·4)*
231·6 
(227·0 to 236·8)
–18·6% 
(–20·5 to –16·6)*
Colon and rectum cancer 896·0 
(876·3 to 915·7)
27·8% 
(24·0 to 31·3)*
11·5 
(11·3 to 11·8)
–4·3% 
(–7·1 to –1·8)*
18 106·7 
(17 678·0 to 
18 525·0)
23·8% 
(19·2 to 27·6)*
224·7 
(219·4 to 229·9)
–4·5% 
(–8·0 to –1·7)*
(Table 1 continues on next page)
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Liver cancer 819·4 
(789·7 to 855·5)
27·0% 
(23·0 to 32·9)*
10·2 
(9·8 to 10·7)
–2·5% 
(–5·6 to 2·0)
20 536·2 
(19 678·7 to 
21 551·9)
21·2% 
(17·0 to 27·4)*
250·7 
(240·4 to 263·0)
–4·6% 
(–8·0 to 0·1)
Liver cancer due to 
hepatitis B
325·4 
(304·6 to 
348·2)
20·3% 
(15·3 to 28·2)*
4·0 
(3·7 to 4·3)
–6·2% 
(–10·0 to 0·1)
9449·0 
(8837·3 to 
10 138·6)
14·7% 
(9·7 to 21·9)*
114·6 
(107·3 to 123·0)
–8·4% 
(–12·2 to –2·6)*
Liver cancer due to 
hepatitis C
234·3 
(219·4 to 250·6)
30·4% 
(26·7 to 35·0)*
3·0 
(2·8 to 3·2)
–2·1% 
(–4·9 to 1·4)
4898·4 
(4554·0 to 5259·3)
26·9% 
(23·3 to 31·6)*
60·3 
(56·2 to 64·7)
–3·0% 
(–5·8 to 0·5)
Liver cancer due to alcohol 
use
129·3 
(114·5 to 147·3)
31·7% 
(26·8 to 37·3)*
1·6 
(1·4 to 1·8)
0·6% 
(–3·0 to 4·8)
3040·7 
(2647·6 to 3549·8)
27·8% 
(22·4 to 33·9)*
37·2 
(32·5 to 43·3)
–0·6% 
(–4·5 to 3·9)
Liver cancer due to NASH 66·9 
(59·6 to 74·5)
42·3% 
(38·0 to 47·6)*
0·8 
(0·8 to 0·9)
7·6% 
(4·4 to 11·7)*
1443·8 
(1288·9 to 1605·9)
37·3% 
(32·7 to 42·8)*
17·8 
(15·9 to 19·7)
6·3% 
(2·9 to 10·5)*
Liver cancer due to other 
causes
63·5 
(57·4 to 70·6)
28·2% 
(23·6 to 34·3)*
0·8 
(0·7 to 0·9)
–0·9% 
(–4·2 to 3·6)
1704·2 
(1528·4 to 1903·8)
21·1% 
(16·0 to 27·4)*
20·9 
(18·8 to 23·3)
–3·5% 
(–7·2 to 1·4)
Gallbladder and biliary tract 
cancer
174·0 
(154·2 to 184·9)
25·0% 
(21·5 to 28·7)*
2·2 
(2·0 to 2·4)
–6·7% 
(–9·4 to –4·0)*
3434·0 
(3009·7 to 3660·0)
21·8% 
(17·8 to 26·3)*
42·6 
(37·3 to 45·4)
–6·8% 
(–9·9 to –3·5)*
Pancreatic cancer 441·1 
(432·8 to 449·0)
39·9% 
(36·7 to 42·6)*
5·6 
(5·5 to 5·7)
4·8% 
(2·5 to 6·8)*
8988·1 
(8806·6 to 9162·9)
35·8% 
(32·5 to 38·6)*
111·1 
(108·9 to 113·2)
4·0% 
(1·5 to 6·1)*
Larynx cancer 126·5 
(123·4 to 129·9)
21·1% 
(17·8 to 24·4)*
1·6 
(1·5 to 1·6)
–7·7% 
(–10·1 to –5·2)*
3170·0 
(3089·7 to 3260·3)
17·3% 
(13·9 to 20·9)*
38·5 
(37·6 to 39·6)
–9·1% 
(–11·7 to –6·4)*
Tracheal, bronchus, and lung 
cancer
1883·1 
(1844·2 to 
1922·8)
29·6% 
(26·5 to 32·5)*
23·7 
(23·3 to 24·2)
–2·0% 
(–4·3 to 0·1)
40 391·6 
(39 506·7 to 
41 285·6)
24·8% 
(21·7 to 27·6)*
496·4 
(485·5 to 507·2)
–4·1% 
(–6·5 to –2·0)*
Malignant skin melanoma 61·7 
(47·9 to 70·3)
23·6% 
(19·0 to 26·9)*
0·8 
(0·6 to 0·9)
–5·1% 
(–8·5 to –2·5)*
1513·2 
(1220·7 to 1774·4)
16·1% 
(12·7 to 20·0)*
18·7 
(15·1 to 21·9)
–7·2% 
(–9·8 to –3·8)*
Non-melanoma skin cancer 65·1 
(63·1 to 66·5)
38·6% 
(34·9 to 41·2)*
0·8 
(0·8 to 0·9)
2·7% 
(0·0 to 4·5)*
1239·1 
(1200·2 to 1266·6)
30·0% 
(26·2 to 32·7)*
15·5 
(15·0 to 15·8)
0·5% 
(–2·3 to 2·6)
Non-melanoma skin cancer 
(squamous-cell carcinoma)
65·1 
(63·1 to 66·5)
38·6% 
(34·9 to 41·2)*
0·8 
(0·8 to 0·9)
2·7% 
(0·0 to 4·5)*
1239·1 
(1200·2 to 1266·6)
30·0% 
(26·2 to 32·7)*
15·5 
(15·0 to 15·8)
0·5% 
(–2·3 to 2·6)
Breast cancer 611·6 
(589·2 to 640·7)
27·0% 
(21·3 to 31·2)*
7·6 
(7·4 to 8·0)
–2·6% 
(–6·9 to 0·4)
16 400·7 
(15 737·0 to 
17 320·2)
23·9% 
(17·3 to 28·7)*
200·2 
(192·1 to 211·4)
–1·7% 
(–6·8 to 2·1)
Cervical cancer 259·7 
(241·1 to 269·2)
18·8% 
(12·9 to 22·8)*
3·2 
(3·0 to 3·3)
–7·2% 
(–11·7 to –4·0)*
7773·5 
(7227·4 to 8087·8)
15·1% 
(9·4 to 19·1)*
94·6 
(88·1 to 98·5)
–7·2% 
(–11·8 to –3·9)*
Uterine cancer 85·2 
(83·2 to 87·4)
18·8% 
(15·8 to 22·5)*
1·1 
(1·0 to 1·1)
–10·4% 
(–12·5 to –7·7)*
1930·0 
(1879·9 to 1983·0)
14·8% 
(11·6 to 19·0)*
23·7 
(23·1 to 24·3)
–11·2% 
(–13·7 to –8·0)*
Ovarian cancer 176·0 
(171·4 to 181·2)
30·3% 
(26·8 to 33·7)*
2·2 
(2·1 to 2·3)
–1·0% 
(–3·6 to 1·6)
4496·9 
(4370·7 to 4642·1)
29·1% 
(24·8 to 33·1)*
54·9 
(53·4 to 56·7)
1·1% 
(–2·2 to 4·2)
Prostate cancer 415·9 
(357·3 to 489·5)
32·5% 
(29·3 to 38·4)*
5·5 
(4·7 to 6·5)
–2·5% 
(–4·9 to 1·9)
6214·5 
(5324·2 to 7293·0)
28·3% 
(24·9 to 34·5)*
79·3 
(68·1 to 93·0)
–3·6% 
(–6·2 to 1·2)
Testicular cancer 7·7 
(7·4 to 8·0)
6·1% 
(2·3 to 10·9)*
0·1 
(0·1 to 0·1)
–9·4% 
(–12·6 to –5·2)*
338·7 
(323·8 to 357·4)
0·9% 
(–3·3 to 6·3)
4·3 
(4·1 to 4·5)
–10·8% 
(–14·5 to –6·1)*
Kidney cancer 138·5 
(128·7 to 142·5)
30·1% 
(26·2 to 34·1)*
1·8 
(1·6 to 1·8)
–1·3% 
(–4·3 to 1·7)
3143·3 
(2952·2 to 3234·1)
23·1% 
(18·5 to 27·3)*
39·4 
(37·0 to 40·5)
–3·3% 
(–6·9 to 0·0)
Bladder cancer 196·5 
(191·5 to 205·8)
27·8% 
(25·1 to 30·4)*
2·6 
(2·5 to 2·7)
–5·4% 
(–7·3 to –3·4)*
3350·1 
(3257·4 to 3511·6)
22·6% 
(19·9 to 25·3)*
42·2 
(41·0 to 44·1)
–6·9% 
(–8·9 to –4·8)*
Brain and nervous system 
cancer
247·1 
(213·0 to 265·0)
29·2% 
(23·2 to 33·4)*
3·1 
(2·7 to 3·3)
3·8% 
(–1·0 to 7·0)
8577·8 
(7527·0 to 9359·3)
18·4% 
(11·9 to 24·6)*
109·8 
(96·1 to 120·0)
0·0% 
(–5·6 to 5·3)
Thyroid cancer 41·2 
(39·9 to 44·1)
28·9% 
(24·3 to 33·3)*
0·5 
(0·5 to 0·6)
–1·2% 
(–4·5 to 2·0)
1001·2 
(963·6 to 1074·0)
22·1% 
(16·7 to 28·0)*
12·4 
(12·0 to 13·4)
–2·3% 
(–6·6 to 2·4)
Mesothelioma 29·9 
(29·1 to 30·6)
26·9% 
(20·1 to 32·6)*
0·4 
(0·4 to 0·4)
–3·4% 
(–8·4 to 0·7)
655·7 
(635·2 to 677·0)
21·0% 
(13·8 to 27·3)*
8·1 
(7·9 to 8·4)
–5·4% 
(–10·8 to –0·8)*
Hodgkin lymphoma 32·6 
(27·6 to 38·1)
0·2% 
(–3·5 to 3·6)
0·4 
(0·4 to 0·5)
–16·8% 
(–19·8 to –14·0)*
1327·6 
(1110·1 to 1567·7)
–5·2% 
(–8·6 to –1·8)*
17·1 
(14·3 to 20·2)
–17·1% 
(–20·1 to –13·9)*
(Table 1 continues on next page)
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All-age deaths (thousands) Age-standardised death rate 
(per 100 000)
All-age YLLs (thousands) Age-standardised YLL rate 
(per 100 000)
2017 Percentage 
change, 2007–17
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change, 2007–17
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change, 2007–17
2017 Percentage 
change, 2007–17
(Continued from previous page)
Non-Hodgkin lymphoma 248·6 
(243·5 to 253·1)
29·4% 
(25·5 to 32·4)*
3·2 
(3·1 to 3·2)
0·1% 
(–2·7 to 2·4)
6828·8 
(6611·8 to 7020·0)
22·1% 
(15·6 to 26·9)*
86·8 
(84·0 to 89·5)
0·2% 
(–5·2 to 4·3)
Multiple myeloma 107·1 
(98·5 to 118·9)
32·7% 
(28·4 to 36·4)*
1·4 
(1·3 to 1·5)
–0·4% 
(–3·5 to 2·4)
2234·7 
(2091·4 to 2493·2)
30·4% 
(25·6 to 34·4)*
27·7 
(25·9 to 30·8)
0·3% 
(–3·3 to 3·4)
Leukaemia 347·6 
(317·3 to 364·9)
12·8% 
(9·5 to 15·6)*
4·5 
(4·1 to 4·7)
–9·6% 
(–12·2 to –7·4)*
11 712·0 
(10 531·4 to 
12 523·3)
2·3% 
(–3·7 to 6·2)
153·4 
(137·9 to 164·5)
–12·0% 
(–17·3 to –8·5)*
Acute lymphoid leukaemia 52·2 
(46·0 to 56·7)
14·1% 
(2·6 to 23·2)*
0·7 
(0·6 to 0·7)
–1·5% 
(–11·6 to 6·2)
2661·7 
(2341·7 to 2941·1)
5·3% 
(–8·6 to 15·4)
36·1 
(31·7 to 40·0)
–4·7% 
(–17·6 to 4·7)
Chronic lymphoid 
leukaemia
35·2 
(33·5 to 36·9)
21·4% 
(17·7 to 25·0)*
0·5 
(0·4 to 0·5)
–10·3% 
(–13·0 to –7·6)*
634·1 
(595·7 to 674·2)
18·3% 
(14·2 to 22·4)*
8·0 
(7·5 to 8·5)
–9·2% 
(–12·3 to –6·1)*
Acute myeloid leukaemia 99·9 
(91·3 to 104·6)
24·6% 
(17·1 to 29·8)*
1·3 
(1·2 to 1·3)
–1·0% 
(–6·6 to 3·0)
3192·6 
(2868·8 to 3405·6)
16·2% 
(4·4 to 24·6)*
41·3 
(37·0 to 44·1)
–1·4% 
(–11·3 to 5·8)
Chronic myeloid leukaemia 24·1 
(22·2 to 26·1)
3·3% 
(0·4 to 6·4)*
0·3 
(0·3 to 0·3)
–19·9% 
(–22·2 to –17·6)*
643·3 
(583·4 to 699·1)
–1·7% 
(–5·2 to 1·5)
8·0 
(7·3 to 8·7)
–19·7% 
(–22·4 to –17·1)*
Other leukaemia 136·2 
(121·0 to 146·8)
4·9% 
(0·9 to 9·7)*
1·8 
(1·6 to 1·9)
–15·6% 
(–18·7 to –12·1)*
4580·2 
(3955·1 to 5013·3)
–8·1% 
(–14·6 to –1·8)*
60·0 
(51·9 to 65·7)
–20·8% 
(–26·5 to –15·4)*
Other malignant cancers 359·5 
(331·4 to 370·8)
26·8% 
(23·3 to 29·5)*
4·6 
(4·2 to 4·8)
0·1% 
(–2·6 to 2·2)
11 189·0 
(10 386·5 to 
11 664·8)
18·4% 
(12·8 to 22·8)*
144·4 
(133·8 to 150·9)
–0·3% 
(–5·1 to 3·5)
Other neoplasms 102·9 
(80·2 to 122·4)
42·0% 
(35·6 to 51·7)*
1·3 
(1·0 to 1·6)
7·4% 
(2·1 to 15·8)*
2425·8 
(2024·4 to 2932·1)
32·9% 
(25·9 to 42·7)*
31·1 
(25·9 to 37·4)
7·9% 
(2·0 to 16·5)*
Myelodysplastic, 
myeloproliferative, and 
other haemopoietic 
neoplasms
98·8 
(76·7 to 118·1)
42·6% 
(36·2 to 52·2)*
1·3 
(1·0 to 1·5)
7·1% 
(1·8 to 15·3)*
2189·1 
(1820·8 to 2665·5)
33·9% 
(26·6 to 43·3)*
27·9 
(23·2 to 33·8)
7·2% 
(1·2 to 15·6)*
Other benign and in-situ 
neoplasms
4·1 
(3·2 to 4·8)
29·6% 
(17·2 to 44·5)*
0·1 
(0·0 to 0·1)
15·5% 
(4·1 to 29·2)*
236·8 
(186·4 to 277·7)
25·0% 
(12·7 to 38·6)*
3·2 
(2·5 to 3·7)
14·3% 
(3·0 to 27·0)*
Cardiovascular diseases 17 790·9 
(17 527·1 to 
18 042·7)
21·1% 
(19·7 to 22·6)*
233·1 
(229·7 to 236·4)
–10·3% 
(–11·4 to –9·3)*
330 172·6 
(324 899·3 to 
335 159·9)
14·7% 
(13·3 to 16·2)*
4148·0 
(4082·0 to 
4210·8)
–11·3% 
(–12·4 to –10·1)*
Rheumatic heart disease 285·5 
(266·2 to 303·3)
1·3% 
(–3·9 to 6·0)
3·7 
(3·4 to 3·9)
–21·3% 
(–25·2 to –17·8)*
7492·6 
(6926·7 to 8046·7)
–10·2% 
(–15·4 to –6·2)*
94·5 
(87·5 to 101·4)
–25·9% 
(–30·0 to –22·7)*
Ischaemic heart disease 8930·4 
(8790·7 to 
9138·7)
22·3% 
(20·6 to 23·8)*
116·9 
(115·1 to 119·7)
–9·7% 
(–11·0 to –8·7)*
164 983·4 
(162 168·9 to 
168 584·2)
17·3% 
(15·4 to 19·0)*
2065·9 
(2030·6 to 
2111·7)
–9·8% 
(–11·2 to –8·5)*
Stroke 6167·3 
(6044·3 to 
6327·6)
16·6% 
(14·7 to 18·6)*
80·5 
(78·9 to 82·6)
–13·6% 
(–15·0 to –12·1)*
113 355·9 
(110 957·8 to 
116 180·6)
12·1% 
(9·9 to 14·1)*
1422·2 
(1392·0 to 
1457·7)
–13·8% 
(–15·5 to –12·3)*
Ischaemic stroke 2747·4 
(2657·1 to 
2857·6)
21·2% 
(19·0 to 23·3)*
36·6 
(35·5 to 38·0)
–11·8% 
(–13·4 to –10·3)*
40 834·1 
(39 133·3 to 
43 140·9)
16·9% 
(14·3 to 19·3)*
521·8 
(500·5 to 550·2)
–12·0% 
(–13·9 to –10·3)*
Intracerebral haemorrhage 2974·9 
(2880·8 to 
3072·8)
12·5% 
(9·6 to 15·1)*
38·2 
(37·0 to 39·4)
–15·7% 
(–17·8 to –13·8)*
61 562·6 
(59 598·2 to 
63 531·4)
9·3% 
(6·5 to 11·8)*
764·1 
(739·7 to 788·4)
–15·4% 
(–17·6 to –13·5)*
Subarachnoid 
haemorrhage
445·0 
(417·2 to 492·3)
18·4% 
(13·4 to 24·6)*
5·7 
(5·3 to 6·3)
–9·4% 
(–13·1 to –4·9)*
10 959·3 
(10 294·3 to 
12 264·1)
10·7% 
(6·8 to 16·5)*
136·4 
(128·2 to 152·5)
–11·4% 
(–14·5 to –7·0)*
Hypertensive heart disease 925·7 
(681·4 to 
994·9)
46·6% 
(26·3 to 59·3)*
12·3 
(9·0 to 13·2)
7·5% 
(–7·3 to 16·3)
15 135·2 
(11 349·8 to 
16 311·7)
35·7% 
(19·1 to 47·9)*
191·5 
(143·3 to 206·2)
3·8% 
(–8·8 to 12·9)
Non-rheumatic valvular heart 
disease
144·9 
(121·8 to 150·4)
31·8% 
(27·7 to 34·7)*
2·0 
(1·6 to 2·0)
–5·3% 
(–7·9 to –3·2)*
2168·4 
(1980·3 to 2322·7)
21·8% 
(18·6 to 25·0)*
27·9 
(25·4 to 29·6)
–6·2% 
(–8·5 to –3·8)*
Non-rheumatic calcific 
aortic valve disease
102·7 
(82·7 to 108·0)
40·0% 
(33·0 to 44·9)*
1·4 
(1·1 to 1·5)
–1·0% 
(–5·6 to 2·2)
1345·1 
(1185·5 to 1432·5)
30·4% 
(25·1 to 35·3)*
17·5 
(15·3 to 18·6)
–1·7% 
(–5·3 to 1·6)
(Table 1 continues on next page)
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Non-rheumatic 
degenerative mitral valve 
disease
35·7 
(30·5 to 42·5)
16·4% 
(11·0 to 23·4)*
0·5 
(0·4 to 0·6)
–14·0% 
(–18·1 to –8·6)*
683·6 
(592·6 to 787·0)
10·3% 
(4·9 to 16·2)*
8·7 
(7·5 to 10·0)
–13·0% 
(–16·9 to –8·3)*
Other non-rheumatic valve 
diseases
6·4 
(4·9 to 8·7)
9·7% 
(–4·1 to 42·2)
0·1 
(0·1 to 0·1)
–17·8% 
(–28·5 to 8·0)
139·7 
(105·8 to 187·5)
8·1% 
(–2·4 to 27·6)
1·8 
(1·4 to 2·4)
–12·4% 
(–21·3 to 4·7)
Cardiomyopathy and 
myocarditis
368·5 
(341·9 to 386·9)
8·1% 
(3·8 to 18·2)*
4·8 
(4·5 to 5·0)
–16·6% 
(–19·8 to –9·4)*
9623·3 
(8867·5 to 
10 208·8)
–5·1% 
(–9·6 to 5·5)
122·4 
(113·0 to 129·7)
–21·5% 
(–25·1 to –13·0)*
Myocarditis 46·5 
(39·7 to 51·8)
14·4% 
(5·6 to 29·7)*
0·6 
(0·5 to 0·7)
–13·3% 
(–20·4 to –0·1)*
1259·3 
(1100·1 to 1415·5)
–0·3% 
(–6·9 to 7·6)
16·6 
(14·5 to 18·5)
–15·2% 
(–21·1 to –7·7)*
Alcoholic cardiomyopathy 88·9 
(80·9 to 96·3)
–25·3% 
(–29·5 to –8·3)*
1·1 
(1·0 to 1·2)
–40·5% 
(–43·7 to –27·6)*
2849·2 
(2599·0 to 3073·1)
–30·7% 
(–34·7 to –12·1)*
34·7 
(31·7 to 37·5)
–43·2% 
(–46·5 to –28·2)*
Other cardiomyopathy 233·2 
(213·7 to 248·3)
28·5% 
(24·5 to 32·4)*
3·1 
(2·8 to 3·3)
–3·6% 
(–6·7 to –0·7)*
5514·8 
(4946·7 to 5992·9)
15·7% 
(10·9 to 19·9)*
71·1 
(64·0 to 77·0)
–5·4% 
(–9·3 to –2·0)*
Atrial fibrillation and flutter 287·2 
(276·4 to 304·8)
47·8% 
(45·4 to 50·6)*
4·0 
(3·9 to 4·2)
2·6% 
(0·9 to 4·6)*
3054·5 
(2923·0 to 3235·4)
40·5% 
(37·9 to 43·4)*
40·6 
(38·9 to 43·1)
2·2% 
(0·3 to 4·2)*
Aortic aneurysm 167·2 
(159·8 to 174·1)
23·7% 
(19·9 to 27·6)*
2·2 
(2·1 to 2·3)
–8·5% 
(–11·2 to –5·8)*
3039·9 
(2877·2 to 3186·4)
19·0% 
(14·5 to 23·6)*
38·2 
(36·2 to 40·0)
–8·5% 
(–11·9 to –5·1)*
Peripheral vascular disease 70·2 
(43·2 to 123·3)
55·7% 
(31·0 to 74·2)*
1·0 
(0·6 to 1·7)
10·5% 
(–6·8 to 24·1)
916·9 
(576·9 to 1540·0)
48·3% 
(25·0 to 65·6)*
11·8 
(7·4 to 20·0)
9·7% 
(–7·5 to 22·6)
Endocarditis 83·4 
(74·3 to 94·3)
32·2% 
(25·2 to 36·8)*
1·1 
(1·0 to 1·2)
1·0% 
(–4·0 to 5·0)
2174·5 
(2033·2 to 2373·0)
16·9% 
(8·9 to 22·2)*
28·3 
(26·4 to 30·9)
–2·3% 
(–8·8 to 2·1)
Other cardiovascular and 
circulatory diseases
360·7 
(338·1 to 392·9)
21·9% 
(17·9 to 24·8)*
4·7 
(4·4 to 5·1)
–7·9% 
(–10·9 to –5·9)*
8228·0 
(7681·4 to 9061·9)
12·6% 
(9·5 to 15·7)*
104·7 
(97·8 to 115·2)
–9·4% 
(–12·0 to –7·1)*
Chronic respiratory diseases 3914·2 
(3790·6 to 
4044·8)
15·8% 
(12·7 to 19·3)*
51·4 
(49·7 to 53·1)
–14·2% 
(–16·5 to –11·5)*
68 004·9 
(65 869·4 to 
70 592·2)
9·7% 
(7·0 to 13·2)*
861·9 
(835·4 to 
895·0)
–15·7% 
(–17·7 to –13·0)*
Chronic obstructive 
pulmonary disease
3197·8 
(3029·0 to 
3358·9)
17·5% 
(13·3 to 21·1)*
42·2 
(40·0 to 44·2)
–13·6% 
(–16·5 to –11·0)*
50 990·0 
(47 678·7 to 
54 146·9)
13·2% 
(8·8 to 16·9)*
647·3 
(605·9 to 
686·4)
–14·3% 
(–17·5 to –11·6)*
Pneumoconiosis 21·6 
(20·5 to 22·7)
10·7% 
(5·1 to 16·6)*
0·3 
(0·3 to 0·3)
–16·7% 
(–20·8 to –12·4)*
426·9 
(403·6 to 452·9)
7·9% 
(1·8 to 14·6)*
5·3 
(5·0 to 5·6)
–16·4% 
(–21·1 to –11·3)*
Silicosis 11·3 
(10·4 to 12·5)
12·0% 
(1·2 to 22·8)*
0·1 
(0·1 to 0·2)
–15·5% 
(–23·6 to –7·4)*
235·7 
(210·3 to 258·2)
11·8% 
(–0·7 to 23·6)
2·9 
(2·6 to 3·2)
–13·4% 
(–23·1 to –4·3)*
Asbestosis 3·4 
(2·3 to 3·9)
23·3% 
(15·1 to 33·9)*
0·0 
(0·0 to 0·1)
–8·3% 
(–14·1 to –0·4)*
54·6 
(38·6 to 65·6)
15·6% 
(7·4 to 28·5)*
0·7 
(0·5 to 0·8)
–11·4% 
(–17·5 to –1·3)*
Coal worker 
pneumoconiosis
3·2 
(2·9 to 4·0)
–2·2% 
(–12·0 to 11·7)
0·0 
(0·0 to 0·1)
–26·6% 
(–33·8 to –16·7)*
58·9 
(52·2 to 76·4)
–6·4% 
(–16·3 to 8·3)
0·7 
(0·7 to 1·0)
–27·9% 
(–35·4 to –16·9)*
Other pneumoconiosis 3·6 
(3·1 to 4·5)
8·9% 
(0·0 to 25·4)*
0·0 
(0·0 to 0·1)
–17·5% 
(–24·1 to –5·0)*
77·6 
(66·1 to 96·4)
4·2% 
(–3·8 to 19·5)
1·0 
(0·8 to 1·2)
–18·3% 
(–24·7 to –5·9)*
Asthma 495·1 
(338·2 to 641·2)
–0·7% 
(–6·2 to 8·1)
6·3 
(4·3 to 8·2)
–23·9% 
(–28·1 to –17·2)*
12 139·9 
(8538·5 to 
15 576·3)
–7·5% 
(–11·4 to –1·6)*
152·8 
(108·3 to 195·8)
–25·8% 
(–28·9 to –20·4)*
Interstitial lung disease and 
pulmonary sarcoidosis
147·6 
(114·9 to 181·3)
49·8% 
(39·0 to 58·6)*
1·9 
(1·5 to 2·4)
11·4% 
(4·0 to 17·9)*
2716·7 
(2156·9 to 3371·3)
43·0% 
(32·1 to 53·4)*
34·2 
(27·1 to 42·4)
10·4% 
(2·3 to 18·6)*
Other chronic respiratory 
diseases
52·1 
(45·9 to 59·6)
21·3% 
(14·1 to 34·2)*
0·7 
(0·6 to 0·8)
–3·2% 
(–8·7 to 6·7)
1731·4 
(1504·5 to 1998·9)
10·8% 
(3·2 to 24·3)*
22·1 
(19·3 to 25·5)
–6·3% 
(–12·6 to 5·3)
Digestive diseases 2377·7 
(2295·1 to 
2518·0)
15·3% 
(12·1 to 19·7)*
30·3 
(29·2 to 32·1)
–10·7% 
(–13·1 to –7·3)*
65 348·4 
(62 343·9 to 
69 371·3)
7·5% 
(4·2 to 11·9)*
819·8 
(781·7 to 
869·7)
–12·2% 
(–14·9 to –8·5)*
Cirrhosis and other chronic 
liver diseases
1322·9 
(1268·2 to 
1449·1)
15·0% 
(8·7 to 21·5)*
16·5 
(15·8 to 18·1)
–9·7% 
(–14·7 to –4·6)*
39 652·4 
(37 985·2 to 
43 624·9)
8·9% 
(3·4 to 14·4)*
488·9 
(468·0 to 537·5)
–11·3% 
(–15·8 to –6·9)*
Cirrhosis and other chronic 
liver diseases due to 
hepatitis B
384·0 
(349·1 to 441·7)
8·6% 
(1·1 to 17·3)*
4·8 
(4·3 to 5·5)
–14·3% 
(–20·2 to –7·3)*
11 721·5 
(10 648·0 to 
13 431·7)
3·4% 
(–3·3 to 10·7)
144·1 
(130·8 to 165·3)
–15·5% 
(–20·9 to –9·5)*
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Cirrhosis and other chronic 
liver diseases due to 
hepatitis C
342·2 
(312·6 to 381·1)
17·4% 
(11·3 to 23·0)*
4·2 
(3·9 to 4·7)
–8·4% 
(–13·0 to –3·9)*
9980·1 
(9074·7 to 
11 116·9)
12·2% 
(6·8 to 17·3)*
121·9 
(111·0 to 135·8)
–9·6% 
(–13·9 to –5·5)*
Cirrhosis and other chronic 
liver diseases due to alcohol 
use
332·3 
(303·0 to 373·3)
16·9% 
(11·2 to 23·7)*
4·1 
(3·7 to 4·6)
–8·8% 
(–13·2 to –3·4)*
9785·4 
(8919·3 to 
10 962·1)
12·3% 
(7·1 to 18·3)*
119·0 
(108·6 to 133·5)
–10·0% 
(–14·2 to –5·2)*
Cirrhosis due to NASH 118·0 
(108·6 to 128·6)
27·6% 
(21·2 to 33·3)*
1·5 
(1·3 to 1·6)
–1·4% 
(–6·3 to 3·1)
3285·5 
(3011·9 to 3586·8)
22·2% 
(16·6 to 27·2)*
40·0 
(36·6 to 43·6)
–3·0% 
(–7·4 to 1·0)
Cirrhosis and other chronic 
liver diseases due to other 
causes
146·4 
(130·9 to 164·6)
14·2% 
(8·2 to 20·2)*
1·9 
(1·7 to 2·1)
–8·6% 
(–13·4 to –3·8)*
4880·0 
(4392·5 to 5457·1)
2·1% 
(–4·3 to 10·7)
63·9 
(57·5 to 71·4)
–12·0% 
(–17·5 to –4·5)*
Upper digestive system 
diseases
292·1 
(279·7 to 312·3)
2·9% 
(–1·3 to 8·6)
3·8 
(3·6 to 4·0)
–21·6% 
(–24·8 to –17·3)*
6789·9 
(6413·1 to 7259·0)
–4·5% 
(–9·5 to 1·8)
85·2 
(80·4 to 91·2)
–23·3% 
(–27·3 to –18·4)*
Peptic ulcer disease 240·3 
(229·4 to 258·8)
0·6% 
(–3·6 to 5·6)
3·1 
(3·0 to 3·3)
–23·5% 
(–26·6 to –19·7)*
5513·3 
(5202·4 to 5947·8)
–6·8% 
(–11·4 to –1·5)*
69·1 
(65·1 to 74·7)
–25·4% 
(–29·0 to –21·0)*
Gastritis and duodenitis 51·8 
(43·0 to 56·9)
15·5% 
(7·5 to 28·9)*
0·7 
(0·6 to 0·7)
–11·7% 
(–17·6 to –2·2)*
1276·6 
(1047·1 to 1419·7)
6·8% 
(–3·1 to 22·4)
16·1 
(13·2 to 17·9)
–13·2% 
(–21·1 to –1·3)*
Appendicitis 43·9 
(40·2 to 47·5)
1·8% 
(–4·0 to 9·6)
0·6 
(0·5 to 0·6)
–17·0% 
(–21·5 to –10·7)*
1633·2 
(1473·2 to 1772·7)
–8·7% 
(–16·7 to 0·6)
21·4 
(19·3 to 23·3)
–20·1% 
(–27·2 to –12·1)*
Paralytic ileus and intestinal 
obstruction
240·5 
(198·7 to 261·6)
21·1% 
(14·4 to 29·0)*
3·2 
(2·7 to 3·5)
–5·8% 
(–11·0 to 0·3)
7245·9 
(5866·8 to 7980·6)
6·5% 
(–3·1 to 15·5)
97·0 
(78·9 to 106·8)
–8·7% 
(–16·8 to –0·8)*
Inguinal, femoral, and 
abdominal hernia
44·2 
(38·6 to 50·0)
21·7% 
(16·2 to 28·4)*
0·6 
(0·5 to 0·7)
–8·9% 
(–12·9 to –4·2)*
914·3 
(792·8 to 1021·9)
12·1% 
(4·5 to 20·4)*
11·7 
(10·1 to 13·1)
–10·6% 
(–16·5 to –3·9)*
Inflammatory bowel disease 38·6 
(31·6 to 41·2)
20·4% 
(11·5 to 27·2)*
0·5 
(0·4 to 0·5)
–10·5% 
(–16·0 to –5·9)*
829·7 
(711·4 to 900·7)
10·3% 
(–2·7 to 19·5)
10·7 
(9·1 to 11·7)
–11·3% 
(–20·7 to –4·5)*
Vascular intestinal disorders 96·1 
(89·0 to 100·8)
22·6% 
(17·0 to 28·1)*
1·3 
(1·2 to 1·3)
–10·2% 
(–14·2 to –6·2)*
1570·1 
(1433·3 to 1667·3)
17·6% 
(10·7 to 24·8)*
20·0 
(18·3 to 21·3)
–10·0% 
(–15·3 to –5·0)*
Gallbladder and biliary 
diseases
110·5 
(105·5 to 116·6)
28·8% 
(25·3 to 33·8)*
1·5 
(1·4 to 1·6)
–5·0% 
(–7·5 to –1·7)*
1983·2 
(1863·2 to 2092·0)
18·5% 
(13·4 to 25·3)*
25·4 
(23·8 to 26·8)
–6·9% 
(–10·9 to –1·8)*
Pancreatitis 101·6 
(89·5 to 108·3)
20·6% 
(16·4 to 25·7)*
1·3 
(1·1 to 1·4)
–5·7% 
(–9·0 to –1·7)*
2890·0 
(2537·1 to 3102·9)
13·8% 
(8·7 to 19·5)*
35·8 
(31·4 to 38·4)
–6·8% 
(–10·9 to –2·1)*
Other digestive diseases 87·3 
(81·9 to 93·3)
25·4% 
(18·1 to 32·3)*
1·2 
(1·1 to 1·2)
–7·1% 
(–12·1 to –2·4)*
1839·7 
(1663·9 to 2038·5)
16·4% 
(5·8 to 27·4)*
23·7 
(21·5 to 26·3)
–6·5% 
(–14·9 to 1·8)
Neurological disorders 3094·2 
(3039·6 to 
3142·6)
42·1% 
(40·2 to 43·9)*
43·1 
(42·3 to 43·7)
0·1% 
(–1·2 to 1·3)
38 004·5 
(37 134·8 to 
39 174·6)
26·2% 
(23·9 to 30·2)*
507·6 
(496·1 to 
523·4)
–3·1% 
(–4·8 to –0·1)*
Alzheimer’s disease and other 
dementias
2514·6 
(2470·5 to 
2550·3)
46·2% 
(43·9 to 48·0)*
35·4 
(34·8 to 35·9)
0·6% 
(–0·9 to 1·8)
23 951·1 
(23 523·6 to 
24 326·8)
38·6% 
(35·7 to 40·9)*
323·7 
(317·9 to 328·7)
–0·3% 
(–2·3 to 1·2)
Parkinson’s disease 340·6 
(324·4 to 355·1)
38·3% 
(33·3 to 41·4)*
4·6 
(4·4 to 4·8)
0·8% 
(–2·8 to 3·0)
4361·2 
(4182·8 to 4578·7)
33·8% 
(28·5 to 37·0)*
56·9 
(54·5 to 59·8)
0·3% 
(–3·6 to 2·6)
Epilepsy 130·2 
(117·0 to 150·8)
3·8% 
(–1·6 to 15·7)
1·7 
(1·5 to 2·0)
–10·7% 
(–15·4 to –0·5)*
6232·1 
(5709·8 to 7289·7)
–5·5% 
(–11·6 to 8·3)
82·6 
(75·5 to 96·6)
–14·9% 
(–20·6 to –2·1)*
Multiple sclerosis 20·7 
(17·7 to 22·2)
22·4% 
(8·0 to 27·8)*
0·3 
(0·2 to 0·3)
–3·9% 
(–14·5 to 0·4)
628·2 
(563·0 to 682·4)
17·1% 
(4·1 to 24·5)*
7·7 
(6·9 to 8·3)
–5·5% 
(–15·1 to 0·6)
Motor neuron disease 34·1 
(32·8 to 37·1)
32·7% 
(28·0 to 37·0)*
0·4 
(0·4 to 0·5)
1·2% 
(–2·4 to 4·5)
828·1 
(796·7 to 917·1)
27·2% 
(22·6 to 31·3)*
10·3 
(9·9 to 11·4)
0·1% 
(–3·5 to 3·3)
Other neurological disorders 53·9 
(51·6 to 59·0)
25·4% 
(17·8 to 32·3)*
0·7 
(0·7 to 0·8)
2·0% 
(–3·9 to 6·8)
2003·8 
(1856·8 to 2269·5)
11·4% 
(3·6 to 21·1)*
26·5 
(24·3 to 30·1)
–2·8% 
(–9·3 to 5·1)
Mental disorders 0·3 
(0·3 to 0·4)
19·9% 
(10·0 to 29·2)*
0·0 
(0·0 to 0·0)
7·5% 
(–1·4 to 15·9)
17·5 
(15·9 to 19·2)
18·5% 
(8·8 to 27·5)*
0·2 
(0·2 to 0·2)
7·2% 
(–1·6 to 15·3)
Eating disorders 0·3 
(0·3 to 0·4)
19·9% 
(10·0 to 29·2)*
0·0 
(0·0 to 0·0)
7·5% 
(–1·4 to 15·9)
17·5 
(15·9 to 19·2)
18·5% 
(8·8 to 27·5)*
0·2 
(0·2 to 0·2)
7·2% 
(–1·6 to 15·3)
Anorexia nervosa 0·2 
(0·2 to 0·3)
17·6% 
(7·0 to 27·6)*
0·0 
(0·0 to 0·0)
5·5% 
(–4·1 to 14·4)
12·7 
(10·9 to 14·1)
15·9% 
(5·6 to 25·6)*
0·2 
(0·1 to 0·2)
5·0% 
(–4·4 to 13·7)
(Table 1 continues on next page)
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Bulimia nervosa 0·1 
(0·1 to 0·1)
26·4% 
(12·9 to 40·5)*
0·0 
(0·0 to 0·0)
13·5% 
(1·0 to 26·2)*
4·8 
(4·0 to 6·7)
25·9% 
(12·0 to 40·0)*
0·1 
(0·1 to 0·1)
13·6% 
(1·1 to 26·3)*
Substance use disorders 351·5 
(334·1 to 362·7)
23·8% 
(20·2 to 27·3)*
4·3 
(4·1 to 4·5)
2·0% 
(–1·0 to 5·0)
13 597·6 
(12 979·5 to 
14 033·3)
18·8% 
(15·3 to 22·4)*
168·0 
(160·4 to 
173·3)
0·8% 
(–2·2 to 3·9)
Alcohol use disorders 184·9 
(166·7 to 193·0)
2·7% 
(–2·2 to 7·7)
2·3 
(2·0 to 2·4)
–16·5% 
(–20·4 to –12·4)*
6750·4 
(6113·2 to 7082·7)
–2·1% 
(–7·2 to 3·3)
82·4 
(74·7 to 86·5)
–18·4% 
(–22·7 to –13·9)*
Drug use disorders 166·6 
(163·4 to 170·3)
60·2% 
(56·9 to 63·6)*
2·1 
(2·0 to 2·1)
34·1% 
(31·4 to 36·9)*
6847·2 
(6704·5 to 7004·4)
50·4% 
(47·0 to 54·0)*
85·5 
(83·7 to 87·5)
30·5% 
(27·6 to 33·5)*
Opioid use disorders 109·5 
(105·7 to 113·6)
77·0% 
(68·8 to 88·5)*
1·4 
(1·3 to 1·4)
49·4% 
(42·5 to 59·2)*
4641·2 
(4480·6 to 4818·9)
65·0% 
(57·3 to 75·0)*
58·0 
(56·1 to 60·3)
43·9% 
(37·1 to 52·6)*
Cocaine use disorders 7·3 
(6·6 to 8·1)
42·2% 
(30·1 to 58·3)*
0·1 
(0·1 to 0·1)
19·6% 
(9·2 to 33·0)*
311·5 
(281·5 to 344·1)
35·6% 
(24·0 to 51·2)*
3·9 
(3·5 to 4·3)
16·7% 
(6·5 to 30·0)*
Amphetamine use 
disorders
4·5 
(3·3 to 5·0)
27·2% 
(0·8 to 41·0)*
0·1 
(0·0 to 0·1)
8·7% 
(–14·0 to 20·7)
206·9 
(151·6 to 227·8)
21·0% 
(–3·6 to 34·4)
2·6 
(1·9 to 2·8)
5·6% 
(–15·5 to 17·4)
Other drug use disorders 45·3 
(42·9 to 48·2)
35·2% 
(22·8 to 46·1)*
0·6 
(0·5 to 0·6)
11·3% 
(1·2 to 19·9)*
1687·6 
(1589·4 to 1805·9)
25·9% 
(14·0 to 37·3)*
21·0 
(19·8 to 22·5)
8·2% 
(–2·0 to 17·8)
Diabetes and kidney 
diseases
2611·2 
(2557·8 to 
2667·2)
34·2% 
(32·0 to 36·2)*
33·6 
(32·9 to 34·3)
1·3% 
(–0·3 to 2·7)
58 116·9 
(56 801·5 to 
59 525·7)
25·1% 
(23·0 to 27·2)*
726·4 
(710·0 to 744·4)
–1·1% 
(–2·8 to 0·6)
Diabetes mellitus 1369·8 
(1340·3 to 
1401·9)
34·7% 
(32·2 to 37·3)*
17·5 
(17·1 to 17·9)
1·2% 
(–0·7 to 3·1)
29 300·2 
(28 711·5 to 
29 950·1)
29·9% 
(27·2 to 32·4)*
363·1 
(355·7 to 371·2)
0·7% 
(–1·4 to 2·6)
Type 1 diabetes mellitus 345·5 
(319·3 to 371·1)
15·1% 
(10·5 to 19·0)*
4·3 
(4·0 to 4·7)
–11·0% 
(–14·6 to –7·8)*
9477·3 
(8944·6 to 
10 079·9)
11·1% 
(7·2 to 14·3)*
117·3 
(110·8 to 124·6)
–10·6% 
(–13·9 to –7·9)*
Type 2 diabetes mellitus 1024·3 
(985·5 to 
1066·8)
43·0% 
(40·4 to 45·8)*
13·2 
(12·7 to 13·7)
5·9% 
(4·1 to 8·0)*
19 822·9 
(19 013·8 to 
20 687·8)
41·3% 
(38·3 to 44·4)*
245·8 
(235·8 to 256·5)
7·1% 
(5·0 to 9·4)*
Chronic kidney disease 1230·2 
(1195·1 to 
1258·8)
33·7% 
(30·5 to 36·1)*
15·9 
(15·5 to 16·3)
1·5% 
(–0·9 to 3·2)
28 508·5 
(27 610·2 to 
29 314·0)
21·0% 
(18·2 to 23·5)*
359·4 
(348·2 to 369·6)
–2·5% 
(–4·7 to –0·6)*
Chronic kidney disease due 
to type 1 diabetes mellitus
77·3 
(62·4 to 95·2)
23·2% 
(19·0 to 27·4)*
0·9 
(0·8 to 1·2)
–1·2% 
(–4·0 to 1·2)
2622·0 
(2121·7 to 3205·5)
17·8% 
(13·6 to 22·3)*
31·9 
(25·9 to 38·9)
–2·9% 
(–5·6 to –0·3)*
Chronic kidney disease due 
to type 2 diabetes mellitus
349·0 
(306·8 to 395·9)
40·5% 
(36·4 to 43·6)*
4·5 
(4·0 to 5·1)
4·2% 
(1·4 to 6·2)*
6671·9 
(5825·5 to 7625·9)
35·4% 
(31·0 to 38·7)*
82·8 
(72·4 to 94·5)
2·9% 
(–0·2 to 5·2)
Chronic kidney disease due 
to hypertension
347·4 
(304·6 to 391·5)
41·4% 
(37·4 to 44·2)*
4·6 
(4·0 to 5·2)
3·2% 
(0·4 to 5·2)*
5954·8 
(5175·1 to 6741·9)
33·4% 
(29·3 to 36·5)*
75·2 
(65·4 to 84·9)
2·3% 
(–0·7 to 4·5)
Chronic kidney disease due 
to glomerulonephritis
189·7 
(165·2 to 217·3)
25·5% 
(22·1 to 28·8)*
2·4 
(2·1 to 2·8)
–1·3% 
(–3·2 to 0·7)
5554·9 
(4929·1 to 6250·8)
12·7% 
(9·6 to 16·1)*
70·6 
(62·8 to 79·4)
–5·5% 
(–7·5 to –3·3)*
Chronic kidney disease due 
to other and unspecified 
causes
266·8 
(232·8 to 304·0)
25·9% 
(22·4 to 29·4)*
3·4 
(3·0 to 3·9)
–1·4% 
(–3·7 to 0·6)
7704·8 
(6794·9 to 8614·8)
10·0% 
(6·8 to 13·4)*
98·9 
(87·4 to 110·0)
–7·7% 
(–9·9 to –5·4)*
Acute glomerulonephritis 11·2 
(10·5 to 12·1)
14·7% 
(8·7 to 22·3)*
0·1 
(0·1 to 0·2)
–9·5% 
(–14·5 to –3·5)*
308·2 
(282·4 to 336·8)
–5·5% 
(–10·4 to 2·2)
3·9 
(3·6 to 4·3)
–20·9% 
(–25·1 to –15·1)*
Skin and subcutaneous 
diseases
100·3 
(65·3 to 131·7)
42·3% 
(34·9 to 52·0)*
1·3 
(0·9 to 1·7)
8·1% 
(2·7 to 16·5)*
2517·9 
(1703·3 to 3283·8)
26·1% 
(18·6 to 35·7)*
33·1 
(22·4 to 43·2)
5·0% 
(–1·2 to 13·8)
Bacterial skin diseases 76·0 
(48·7 to 95·6)
45·5% 
(36·8 to 54·9)*
1·0 
(0·6 to 1·3)
12·7% 
(6·0 to 20·7)*
2096·6 
(1378·0 to 2691·9)
26·4% 
(18·0 to 36·9)*
27·6 
(18·2 to 35·6)
6·4% 
(–0·6 to 15·9)
Cellulitis 18·9 
(10·3 to 26·0)
57·0% 
(45·8 to 67·1)*
0·2 
(0·1 to 0·3)
19·6% 
(9·8 to 28·2)*
480·1 
(264·6 to 640·2)
38·3% 
(30·8 to 50·4)*
6·2 
(3·4 to 8·3)
13·7% 
(7·3 to 23·9)*
Pyoderma 57·1 
(35·8 to 70·8)
42·1% 
(32·4 to 52·4)*
0·8 
(0·5 to 0·9)
10·5% 
(3·2 to 19·0)*
1616·4 
(1051·6 to 2136·7)
23·3% 
(14·3 to 35·0)*
21·5 
(14·1 to 28·8)
4·5% 
(–3·2 to 15·0)
Decubitus ulcer 20·3 
(13·2 to 30·6)
32·4% 
(22·9 to 51·0)*
0·3 
(0·2 to 0·4)
–5·1% 
(–12·2 to 9·2)
321·7 
(211·2 to 471·5)
26·2% 
(17·9 to 42·5)*
4·2 
(2·7 to 6·1)
–2·3% 
(–8·8 to 11·5)
(Table 1 continues on next page)
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(per 100 000)
All-age YLLs (thousands) Age-standardised YLL rate 
(per 100 000)
2017 Percentage 
change, 2007–17
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change, 2007–17
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
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Other skin and subcutaneous 
diseases
3·9 
(2·6 to 7·2)
35·8% 
(26·6 to 49·6)*
0·1 
(0·0 to 0·1)
3·3% 
(–3·5 to 14·4)
99·6 
(69·4 to 165·8)
19·1% 
(10·8 to 34·1)*
1·3 
(0·9 to 2·2)
0·7% 
(–6·1 to 13·1)
Musculoskeletal disorders 121·3 
(105·6 to 126·2)
30·9% 
(25·1 to 35·1)*
1·6 
(1·4 to 1·6)
–0·1% 
(–4·4 to 3·2)
2842·7 
(2440·7 to 2953·1)
19·6% 
(13·7 to 23·2)*
35·9 
(30·8 to 37·3)
–2·5% 
(–7·1 to 0·4)
Rheumatoid arthritis 47·3 
(39·0 to 51·2)
25·8% 
(16·2 to 31·9)*
0·6 
(0·5 to 0·7)
–5·9% 
(–12·9 to –1·2)*
866·0 
(707·8 to 941·4)
17·9% 
(8·6 to 23·3)*
10·9 
(8·9 to 11·8)
–9·1% 
(–16·1 to –5·0)*
Other musculoskeletal 
disorders
74·0 
(66·1 to 78·7)
34·4% 
(30·2 to 38·8)*
1·0 
(0·9 to 1·0)
3·9% 
(0·9 to 7·5)*
1976·6 
(1730·3 to 2089·1)
20·3% 
(15·6 to 24·0)*
25·0 
(21·9 to 26·4)
0·8% 
(–3·0 to 3·8)
Other non-communicable 
diseases
1153·3 
(1101·8 to 
1208·3)
0·8% 
(–3·9 to 4·0)
16·3 
(15·5 to 17·1)
–11·2% 
(–15·3 to –8·5)*
68 240·8 
(64 835·4 to 
72 452·1)
–10·6% 
(–15·8 to –6·9)*
993·0 
(941·3 to 
1054·3)
–16·4% 
(–21·3 to –12·8)*
Congenital anomalies 584·9 
(556·3 to 618·3)
–14·3% 
(–21·1 to –10·1)*
8·7 
(8·2 to 9·2)
–18·2% 
(–24·7 to –14·1)*
48 860·4 
(46 405·7 to 
51 687·3)
–15·3% 
(–22·0 to –11·0)*
729·4 
(692·5 to 771·7)
–18·8% 
(–25·2 to –14·6)*
Neural tube defects 61·7 
(46·7 to 83·7)
–13·1% 
(–24·5 to –1·0)*
0·9 
(0·7 to 1·3)
–16·5% 
(–27·6 to –4·8)*
5317·5 
(4017·1 to 7217·5)
–13·4% 
(–24·8 to –1·4)*
80·0 
(60·4 to 108·6)
–16·7% 
(–27·7 to –5·0)*
Congenital heart anomalies 261·2 
(216·6 to 308·2)
–17·9% 
(–24·6 to –9·8)*
3·9 
(3·2 to 4·6)
–21·8% 
(–28·1 to –14·1)*
21 634·4 
(17 770·6 to 
25 604·8)
–18·9% 
(–25·5 to –10·8)*
321·7 
(263·6 to 381·4)
–22·4% 
(–28·7 to –14·6)*
Orofacial clefts 3·8 
(1·5 to 8·8)
–40·0% 
(–54·5 to –22·5)*
0·1 
(0·0 to 0·1)
–41·9% 
(–55·9 to –25·1)*
331·3 
(130·1 to 770·5)
–40·0% 
(–54·5 to –22·7)*
5·0 
(2·0 to 11·7)
–41·9% 
(–56·0 to –25·2)*
Down syndrome 26·1 
(21·3 to 35·1)
3·1% 
(–7·4 to 17·4)
0·4 
(0·3 to 0·5)
–5·2% 
(–14·2 to 7·0)
1906·1 
(1481·7 to 2707·9)
–1·4% 
(–11·5 to 13·9)
27·7 
(21·3 to 39·8)
–7·3% 
(–16·7 to 7·1)
Other chromosomal 
abnormalities
17·9 
(12·0 to 26·3)
4·6% 
(–6·3 to 18·2)
0·3 
(0·2 to 0·4)
0·3% 
(–10·1 to 13·2)
1507·9 
(1012·2 to 2233·3)
3·9% 
(–6·9 to 17·4)
22·6 
(15·1 to 33·5)
0·0% 
(–10·4 to 13·0)
Congenital musculoskeletal 
and limb anomalies
11·0 
(8·6 to 14·0)
–8·7% 
(–17·3 to 0·0)
0·2 
(0·1 to 0·2)
–12·8% 
(–20·9 to –4·5)*
912·2 
(708·9 to 1172·9)
–9·8% 
(–18·2 to –1·0)*
13·6 
(10·6 to 17·5)
–13·3% 
(–21·5 to –4·9)*
Urogenital congenital 
anomalies
14·1 
(10·3 to 16·9)
–2·5% 
(–11·8 to 9·2)
0·2 
(0·1 to 0·2)
–8·5% 
(–17·1 to 2·1)
1105·8 
(781·3 to 1347·8)
–5·5% 
(–14·6 to 6·3)
16·4 
(11·5 to 20·0)
–9·7% 
(–18·3 to 1·3)
Digestive congenital 
anomalies
50·8 
(37·7 to 71·8)
–16·2% 
(–27·1 to –6·4)*
0·8 
(0·6 to 1·1)
–19·3% 
(–29·8 to –9·8)*
4398·7 
(3253·9 to 6229·0)
–16·5% 
(–27·3 to –6·7)*
66·3 
(49·0 to 93·9)
–19·4% 
(–29·9 to –9·9)*
Other congenital 
anomalies
138·3 
(102·3 to 175·6)
–12·4% 
(–20·1 to –0·5)*
2·1 
(1·5 to 2·6)
–15·9% 
(–23·3 to –4·5)*
11 746·6 
(8613·3 to 
14 951·0)
–13·0% 
(–20·7 to –1·1)*
176·1 
(128·8 to 224·2)
–16·3% 
(–23·7 to –4·8)*
Urinary diseases and male 
infertility
271·2 
(263·9 to 282·2)
39·6% 
(34·9 to 43·4)*
3·6 
(3·5 to 3·7)
5·7% 
(2·2 to 8·5)*
6255·2 
(6044·8 to 6542·1)
20·8% 
(15·5 to 24·9)*
81·1 
(78·3 to 84·8)
–0·7% 
(–5·1 to 2·7)
Urinary tract infections 206·4 
(197·9 to 223·2)
48·3% 
(42·9 to 53·5)*
2·7 
(2·6 to 3·0)
10·9% 
(7·2 to 14·5)*
4522·3 
(4285·2 to 5016·3)
31·4% 
(24·4 to 38·8)*
58·4 
(55·2 to 65·0)
7·2% 
(1·7 to 13·0)*
Urolithiasis 12·3 
(10·5 to 15·7)
30·4% 
(19·0 to 49·4)*
0·2 
(0·1 to 0·2)
–1·2% 
(–9·7 to 12·9)
255·1 
(216·0 to 323·5)
19·6% 
(9·7 to 36·9)*
3·2 
(2·7 to 4·0)
–5·9% 
(–13·6 to 7·7)
Other urinary diseases 52·5 
(42·3 to 58·0)
15·0% 
(8·0 to 25·5)*
0·7 
(0·6 to 0·8)
–9·9% 
(–15·3 to –2·2)*
1477·8 
(1172·2 to 1660·2)
–3·0% 
(–9·6 to 6·4)
19·4 
(15·4 to 21·9)
–18·2% 
(–23·3 to –10·6)*
Gynaecological diseases 8·2 
(7·4 to 8·7)
19·1% 
(5·1 to 30·0)*
0·1 
(0·1 to 0·1)
–2·6% 
(–13·6 to 6·0)
292·9 
(272·6 to 318·7)
9·2% 
(–2·8 to 20·6)
3·7 
(3·4 to 4·0)
–6·0% 
(–15·4 to 3·6)
Uterine fibroids 2·4 
(1·6 to 3·0)
33·3% 
(6·7 to 54·6)*
0·0 
(0·0 to 0·0)
8·1% 
(–14·9 to 24·7)
74·2 
(52·7 to 95·5)
13·0% 
(–4·2 to 31·6)
0·9 
(0·6 to 1·2)
–4·8% 
(–20·0 to 10·5)
Polycystic ovarian 
syndrome
0·0 
(0·0 to 0·0)
12·9% 
(–12·8 to 50·4)
0·0 
(0·0 to 0·0)
1·0% 
(–22·5 to 34·8)
0·7 
(0·1 to 1·5)
10·1% 
(–15·8 to 51·2)
0·0 
(0·0 to 0·0)
–0·1% 
(–24·3 to 37·2)
Endometriosis 0·2 
(0·1 to 0·2)
11·8% 
(–12·4 to 45·5)
0·0 
(0·0 to 0·0)
–3·2% 
(–23·8 to 25·5)
7·7 
(3·2 to 12·0)
10·4% 
(–12·9 to 41·7)
0·1 
(0·0 to 0·1)
–3·2% 
(–23·2 to 24·3)
Genital prolapse 0·6 
(0·3 to 0·9)
0·6% 
(–15·4 to 16·1)
0·0 
(0·0 to 0·0)
–24·1% 
(–36·0 to –13·0)*
14·5 
(6·8 to 20·1)
–4·4% 
(–18·4 to 10·4)
0·2 
(0·1 to 0·2)
–24·0% 
(–35·2 to –11·9)*
Other gynaecological 
diseases
5·0 
(4·1 to 5·6)
16·0% 
(4·1 to 27·9)*
0·1 
(0·1 to 0·1)
–3·6% 
(–12·2 to 5·9)
195·8 
(163·0 to 228·9)
8·9% 
(–2·9 to 20·6)
2·5 
(2·1 to 2·9)
–4·8% 
(–14·2 to 5·1)
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Haemoglobinopathies and 
haemolytic anaemias
104·6 
(82·0 to 132·2)
5·8% 
(–1·4 to 13·4)
1·4 
(1·1 to 1·8)
–11·3% 
(–17·6 to –4·8)*
4831·6 
(3643·1 to 6268·9)
–1·8% 
(–13·1 to 9·4)
66·6 
(50·0 to 86·2)
–11·1% 
(–21·6 to –0·5)*
Thalassaemias 7·2 
(6·0 to 8·4)
–23·7% 
(–32·6 to –12·7)*
0·1 
(0·1 to 0·1)
–27·9% 
(–36·5 to –17·2)*
564·7 
(474·8 to 667·6)
–24·6% 
(–33·9 to –13·2)*
8·2 
(6·9 to 9·7)
–28·6% 
(–37·6 to –17·6)*
Sickle cell disorders 38·4 
(24·0 to 54·8)
3·7% 
(–11·6 to 17·7)
0·5 
(0·3 to 0·8)
–3·1% 
(–17·6 to 10·3)
2796·4 
(1747·3 to 3913·6)
2·1% 
(–13·7 to 17·3)
39·7 
(24·8 to 55·3)
–3·9% 
(–19·1 to 11·0)
G6PD deficiency 16·7 
(12·1 to 22·5)
11·8% 
(4·7 to 19·6)*
0·2 
(0·2 to 0·3)
–7·1% 
(–12·1 to –1·0)*
692·6 
(522·0 to 896·1)
4·4% 
(–2·5 to 12·3)
8·8 
(6·7 to 11·4)
–9·6% 
(–15·0 to –3·3)*
Other 
haemoglobinopathies and 
haemolytic anaemias
42·2 
(35·1 to 49·2)
13·0% 
(9·3 to 16·5)*
0·6 
(0·5 to 0·6)
–16·1% 
(–18·7 to –13·4)*
777·8 
(634·5 to 917·2)
1·3% 
(–2·2 to 4·8)
9·9 
(8·1 to 11·7)
–19·9% 
(–22·3 to –17·4)*
Endocrine, metabolic, blood, 
and immune disorders
144·5 
(115·1 to 152·3)
28·2% 
(19·7 to 33·3)*
1·9 
(1·5 to 2·0)
0·8% 
(–5·0 to 4·4)
4506·4 
(3762·3 to 4919·9)
10·4% 
(2·7 to 16·9)*
59·7 
(50·0 to 65·5)
–5·5% 
(–11·2 to –0·2)*
Sudden infant death 
syndrome
40·0 
(18·0 to 77·0)
–17·3% 
(–28·6 to –1·4)*
0·6 
(0·3 to 1·2)
–20·2% 
(–31·2 to –4·9)*
3494·3 
(1570·1 to 6734·0)
–17·3% 
(–28·6 to –1·4)*
52·7 
(23·7 to 101·5)
–20·2% 
(–31·2 to –4·9)*
Injuries 4484·7 
(4332·0 to 
4585·6)
2·3% 
(0·5 to 4·0)*
57·9 
(55·9 to 59·2)
–13·7% 
(–15·1 to –12·2)*
195 231·1 
(188 807·7 to 
199 825·5)
–6·4% 
(–7·8 to –4·8)*
2548·3 
(2461·9 to 
2609·6)
–16·9% 
(–18·2 to –15·3)*
Transport injuries 1335·0 
(1289·1 to 
1369·5)
–3·1% 
(–6·0 to –0·6)*
17·0 
(16·4 to 17·4)
–17·0% 
(–19·5 to –14·9)*
61 937·8 
(60 031·2 to 
63 736·5)
–9·6% 
(–11·8 to –7·3)*
800·5 
(775·9 to 
823·3)
–19·5% 
(–21·4 to –17·5)*
Road injuries 1243·1 
(1191·9 to 
1276·9)
–3·2% 
(–6·3 to –0·5)*
15·8 
(15·2 to 16·3)
–17·1% 
(–19·7 to –14·9)*
57 638·4 
(55 500·8 to 
59 369·2)
–9·7% 
(–12·0 to –7·3)*
745·0 
(718·1 to 767·4)
–19·6% 
(–21·6 to –17·5)*
Pedestrian road injuries 486·2 
(459·7 to 535·0)
–6·4% 
(–11·7 to –2·1)*
6·2 
(5·9 to 6·8)
–21·4% 
(–25·5 to –17·9)*
20 850·8 
(19 596·0 to 
23 164·4)
–14·8% 
(–18·7 to –11·0)*
270·4 
(253·9 to 300·8)
–25·1% 
(–28·3 to –21·9)*
Cyclist road injuries 68·9 
(59·2 to 76·2)
9·1% 
(1·8 to 16·4)*
0·9 
(0·7 to 1·0)
–8·8% 
(–14·8 to –2·5)*
2853·5 
(2471·6 to 3209·0)
1·0% 
(–5·7 to 8·3)
36·3 
(31·5 to 41·0)
–11·8% 
(–17·8 to –5·3)*
Motorcyclist road injuries 225·7 
(196·1 to 238·6)
–0·6% 
(–8·9 to 5·2)
2·9 
(2·5 to 3·0)
–12·4% 
(–19·5 to –7·3)*
11 416·3 
(9969·6 to 
12 098·0)
–5·7% 
(–12·5 to –0·5)*
146·2 
(127·5 to 154·9)
–14·8% 
(–20·7 to –10·1)*
Motor vehicle road injuries 451·1 
(423·4 to 472·9)
–2·5% 
(–6·2 to 1·3)
5·8 
(5·4 to 6·0)
–15·6% 
(–18·6 to –12·2)*
22 004·1 
(20 639·8 to 
23 130·9)
–7·8% 
(–10·4 to –3·0)*
285·3 
(267·6 to 299·7)
–17·2% 
(–19·6 to –12·8)*
Other road injuries 11·2 
(9·9 to 12·8)
–5·5% 
(–11·0 to 16·1)
0·1 
(0·1 to 0·2)
–19·4% 
(–24·1 to –1·3)*
513·8 
(454·1 to 583·4)
–11·7% 
(–17·3 to 10·6)
6·7 
(5·9 to 7·6)
–21·4% 
(–26·5 to –1·7)*
Other transport injuries 91·9 
(84·5 to 107·2)
–1·5% 
(–6·2 to 3·7)
1·2 
(1·1 to 1·4)
–15·5% 
(–19·5 to –10·9)*
4299·4 
(3919·6 to 5048·3)
–7·8% 
(–12·6 to –2·4)*
55·4 
(50·5 to 65·0)
–17·9% 
(–22·2 to –13·2)*
Unintentional injuries 1804·9 
(1695·7 to 
1872·0)
2·9% 
(0·5 to 6·0)*
23·8 
(22·4 to 24·7)
–15·3% 
(–17·3 to –12·8)*
69 430·5 
(64 685·1 to 
72 366·8)
–12·8% 
(–15·0 to –9·6)*
928·8 
(865·6 to 
969·3)
–23·0% 
(–25·0 to 
–20·0)*
Falls 695·8 
(644·9 to 741·7)
27·4% 
(21·2 to 35·6)*
9·2 
(8·5 to 9·8)
–2·8% 
(–7·4 to 3·4)
16 688·1 
(15 101·9 to 
17 636·8)
10·1% 
(4·8 to 17·2)*
216·6 
(196·4 to 228·6)
–8·4% 
(–12·7 to –2·5)*
Drowning 295·2 
(284·5 to 306·2)
–17·2% 
(–19·8 to –14·1)*
4·0 
(3·8 to 4·1)
–27·3% 
(–29·6 to –24·5)*
16 563·3 
(15 784·2 to 
17 350·0)
–26·1% 
(–29·0 to –22·4)*
228·3 
(217·2 to 239·7)
–32·8% 
(–35·5 to –29·3)*
Fire  heat  and hot substances 120·6 
(101·6 to 129·4)
–7·9% 
(–10·9 to –1·2)*
1·6 
(1·3 to 1·7)
–22·9% 
(–25·4 to –17·3)*
5286·3 
(4308·9 to 5836·4)
–16·5% 
(–21·0 to –7·3)*
71·0 
(57·8 to 78·6)
–25·5% 
(–29·6 to –17·1)*
Poisonings 72·4 
(52·7 to 79·4)
–6·8% 
(–16·1 to 2·9)
0·9 
(0·7 to 1·0)
–20·8% 
(–28·4 to –12·5)*
3321·7 
(2454·1 to 3669·2)
–14·6% 
(–22·7 to –3·8)*
44·1 
(32·7 to 48·8)
–23·9% 
(–31·0 to –14·1)*
Poisoning by carbon 
monoxide
35·5 
(25·7 to 38·8)
–12·5% 
(–22·4 to –5·0)*
0·5 
(0·3 to 0·5)
–26·6% 
(–34·8 to –20·3)*
1462·4 
(1073·0 to 1613·6)
–19·1% 
(–27·2 to –11·8)*
18·9 
(13·8 to 20·9)
–29·0% 
(–36·2 to –22·4)*
Poisoning by other means 36·9 
(26·8 to 41·0)
–0·5% 
(–10·1 to 11·9)
0·5 
(0·4 to 0·5)
–14·4% 
(–22·4 to –3·9)*
1859·3 
(1385·8 to 2072·9)
–10·7% 
(–19·6 to 3·3)
25·2 
(19·0 to 28·1)
–19·6% 
(–27·7 to –6·8)*
(Table 1 continues on next page)
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All-age deaths (thousands) Age-standardised death rate 
(per 100 000)
All-age YLLs (thousands) Age-standardised YLL rate 
(per 100 000)
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
(Continued from previous page)
Exposure to mechanical 
forces
136·5 
(117·6 to 143·2)
–6·7% 
(–9·8 to –3·7)*
1·8 
(1·5 to 1·8)
–20·3% 
(–22·9 to –17·8)*
6385·5 
(5500·4 to 6710·8)
–13·8% 
(–16·6 to –10·8)*
84·0 
(72·3 to 88·3)
–23·0% 
(–25·5 to –20·3)*
Unintentional firearm 
injuries
22·6 
(21·1 to 25·8)
–2·9% 
(–7·5 to 2·8)
0·3 
(0·3 to 0·3)
–16·4% 
(–20·3 to –11·5)*
1094·5 
(1013·5 to 1275·4)
–7·4% 
(–12·2 to –1·3)*
14·4 
(13·3 to 16·9)
–16·5% 
(–20·9 to –11·1)*
Other exposure to 
mechanical forces
113·9 
(94·7 to 120·8)
–7·4% 
(–10·6 to –4·1)*
1·5 
(1·2 to 1·6)
–21·0% 
(–23·7 to –18·3)*
5291·0 
(4401·1 to 5626·1)
–15·0% 
(–18·0 to –11·7)*
69·6 
(57·8 to 74·0)
–24·3% 
(–26·9 to –21·2)*
Adverse effects of medical 
treatment
121·6 
(103·6 to 137·6)
16·6% 
(12·0 to 20·9)*
1·6 
(1·4 to 1·8)
–6·2% 
(–10·0 to –2·5)*
4363·9 
(3619·9 to 5234·0)
4·0% 
(–1·2 to 11·0)
58·1 
(48·0 to 70·7)
–9·5% 
(–13·9 to –3·6)*
Animal contact 81·1 
(44·9 to 94·0)
–1·4% 
(–6·8 to 6·2)
1·1 
(0·6 to 1·2)
–16·0% 
(–20·5 to –9·6)*
3911·9 
(2167·6 to 4585·6)
–9·5% 
(–15·8 to 0·2)
52·4 
(29·0 to 61·8)
–19·2% 
(–25·2 to –10·2)*
Venomous animal contact 70·9 
(37·0 to 83·8)
–1·3% 
(–7·5 to 6·2)
0·9 
(0·5 to 1·1)
–16·0% 
(–21·0 to –9·7)*
3407·7 
(1758·4 to 4087·5)
–9·7% 
(–16·4 to –0·7)*
45·5 
(23·4 to 54·9)
–19·4% 
(–25·8 to –11·3)*
Non-venomous animal 
contact
10·1 
(7·1 to 14·4)
–1·6% 
(–15·3 to 10·2)
0·1 
(0·1 to 0·2)
–16·1% 
(–27·4 to –6·2)*
504·2 
(335·8 to 750·1)
–7·9% 
(–26·1 to 6·5)
6·9 
(4·5 to 10·3)
–17·2% 
(–33·6 to –4·3)*
Foreign body 124·1 
(119·3 to 130·0)
1·7% 
(–1·9 to 4·8)
1·7 
(1·6 to 1·8)
–14·1% 
(–17·0 to –11·6)*
5907·0 
(5566·3 to 6301·2)
–12·4% 
(–16·4 to –8·3)*
83·3 
(78·3 to 88·9)
–20·1% 
(–23·8 to –16·3)*
Pulmonary aspiration and 
foreign body in airway
115·7 
(111·4 to 121·3)
1·9% 
(–1·9 to 5·0)
1·6 
(1·5 to 1·7)
–13·9% 
(–17·0 to –11·4)*
5526·1 
(5212·6 to 5910·0)
–12·2% 
(–16·6 to –8·0)*
78·1 
(73·5 to 83·7)
–19·9% 
(–23·8 to –16·0)*
Foreign body in other body 
part
8·4 
(7·5 to 10·3)
–0·5% 
(–6·9 to 7·1)
0·1 
(0·1 to 0·1)
–15·8% 
(–20·8 to –10·0)*
381·0 
(326·2 to 474·4)
–14·4% 
(–21·1 to –6·2)*
5·2 
(4·4 to 6·5)
–23·3% 
(–29·2 to –16·1)*
Environmental heat and cold 
exposure
53·3 
(36·8 to 59·2)
–13·2% 
(–22·4 to –8·4)*
0·7 
(0·5 to 0·8)
–29·4% 
(–37·1 to –25·4)*
1845·6 
(1246·6 to 2066·2)
–21·4% 
(–28·8 to –17·5)*
23·7 
(15·8 to 26·7)
–32·7% 
(–39·5 to –29·1)*
Exposure to forces of nature 9·6 
(8·7 to 11·0)
–38·0% 
(–43·9 to –28·9)*
0·1 
(0·1 to 0·1)
–45·8% 
(–50·8 to –37·9)*
477·6 
(438·4 to 544·3)
–45·0% 
(–49·4 to –37·3)*
6·3 
(5·8 to 7·2)
–50·2% 
(–54·2 to –43·2)*
Other unintentional injuries 94·7 
(91·9 to 98·3)
–14·5% 
(–16·7 to –12·1)*
1·2 
(1·2 to 1·3)
–25·8% 
(–27·6 to –23·8)*
4679·6 
(4519·4 to 4888·2)
–20·7% 
(–22·9 to –18·1)*
60·9 
(58·8 to 63·7)
–28·9% 
(–30·9 to –26·6)*
Self-harm and interpersonal 
violence
1344·8 
(1283·1 to 
1380·4)
7·3% 
(4·6 to 9·7)*
17·1 
(16·3 to 17·5)
–7·6% 
(–9·9 to –5·5)*
63 862·9 
(61 029·9 to 
65 755·7)
5·4% 
(2·8 to 7·7)*
819·0 
(782·2 to 
843·4)
–5·7% 
(–7·9 to –3·7)*
Self-harm 793·8 
(743·5 to 819·7)
1·1% 
(–2·6 to 3·7)
10·0 
(9·4 to 10·3)
–14·8% 
(–18·0 to –12·6)*
33 577·2 
(31 449·3 to 
34 719·1)
–3·4% 
(–7·0 to –0·9)*
423·6 
(396·9 to 438·2)
–15·1% 
(–18·4 to –12·9)*
Self-harm by firearm 63·8 
(54·6 to 78·6)
6·8% 
(2·3 to 10·8)*
0·8 
(0·7 to 1·0)
–10·3% 
(–13·9 to –7·2)*
2653·6 
(2241·9 to 3288·1)
0·9% 
(–3·5 to 5·5)
33·5 
(28·2 to 41·6)
–11·5% 
(–15·2 to –7·6)*
Self-harm by other 
specified means
730·0 
(678·5 to 754·9)
0·6% 
(–3·2 to 3·4)
9·2 
(8·5 to 9·5)
–15·2% 
(–18·4 to –12·8)*
30 923·6 
(28 832·4 to 
32 098·2)
–3·7% 
(–7·5 to –1·1)*
390·1 
(363·6 to 405·1)
–15·4% 
(–18·8 to –13·1)*
Interpersonal violence 405·3 
(365·2 to 431·7)
0·5% 
(–2·0 to 3·2)
5·2 
(4·7 to 5·5)
–11·1% 
(–13·3 to –8·7)*
21 439·8 
(19 275·8 to 
22 799·8)
–1·6% 
(–4·4 to 1·3)
276·8 
(248·4 to 294·2)
–10·9% 
(–13·4 to –8·2)*
Assault by firearm 174·4 
(147·9 to 188·9)
7·5% 
(4·3 to 10·8)*
2·2 
(1·9 to 2·4)
–3·6% 
(–6·5 to –0·5)*
9541·2 
(8106·2 to 
10 291·7)
5·4% 
(2·1 to 9·0)*
122·9 
(104·3 to 132·4)
–3·7% 
(–6·7 to –0·4)*
Assault by sharp object 91·4 
(74·4 to 111·2)
–11·5% 
(–15·3 to –6·0)*
1·2 
(0·9 to 1·4)
–22·3% 
(–25·6 to –17·6)*
4634·5 
(3747·0 to 5648·9)
–13·9% 
(–17·6 to –8·5)*
59·2 
(47·8 to 72·1)
–22·6% 
(–25·9 to –17·8)*
Assault by other means 139·5 
(123·6 to 164·4)
1·3% 
(–3·4 to 5·6)
1·8 
(1·6 to 2·1)
–11·5% 
(–15·4 to –7·6)*
7264·1 
(6400·8 to 8583·0)
–1·3% 
(–5·4 to 3·6)
94·7 
(83·3 to 111·5)
–11·2% 
(–14·9 to –6·8)*
Conflict and terrorism 129·7 
(118·1 to 143·2)
118·0% 
(88·8 to 148·6)*
1·7 
(1·6 to 1·9)
98·4% 
(72·4 to 126·1)*
7966·6 
(7244·5 to 8855·9)
113·5% 
(84·5 to 146·8)*
107·3 
(97·6 to 119·1)
97·9% 
(71·0 to 128·8)*
Executions and police conflict 16·0 
(15·7 to 16·3)
203·9% 
(186·9 to 220·9)*
0·2 
(0·2 to 0·2)
172·4% 
(156·8 to 187·6)*
879·3 
(862·3 to 898·1)
202·1% 
(184·8 to 219·8)*
11·4 
(11·2 to 11·7)
176·4% 
(160·5 to 192·9)*
Data in parentheses are 95% uncertainty intervals. G6PD=glucose-6-phosphate dehydrogenase. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. H influenzae=Haemophilus influenzae. 
NASH=non-alcoholic steatohepatitis. YLL=years of life lost. *Percentage changes that are statistically significant.
Table 1: Global death and YLL numbers, age-standardised rates per 100 000, and percentage change between 2007 and 2017 for both sexes combined for all GBD causes and Levels 1 
through 4 of the cause hierarchy
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age-sex-cause death rate using GBD estimates from all 
national locations across all years from 1980 to 2017 
(appendix 1 section 7). Expected cause-specific death rates 
were scaled to the expected all-cause death rate to ensure 
internal consistency. We then computed the number of 
YLLs and deaths expected for each age-sex-location-year 
based on SDI alone and compared these estimates to 
observed rates. Additional details of the development and 
calculation of SDI for GBD 2017 are described in 
appendix 1 (section 5).
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
All authors had full access to all the data in the study 
and had final responsibility for the decision to submit 
for publication.
Results
Global causes of death
Mortality estimates by cause for the years 1990, 2007, and 
2017 are available by age and sex through the GBD results 
tool and for each year in the GBD estimation period 
1980–2017 through the online data visualisation tool. All 
reported rates are age-standardised.
In 2017, at the broadest level of cause of death 
classification in the GBD cause list (Level 1), CMNN 
causes accounted for 18·6% (95% UI 17·9–19·6) of 
total deaths or 10·4 million (10·0–11·0) deaths in 2017, 
while non-communicable causes (NCDs) accounted for 
73·4% (72·5–74·1) or 41·1 million (40·5–41·5) deaths, 
and injuries accounted for 8·0% (7·7–8·2) of deaths or 
4·48 million (4·33–4·59) deaths (table 1). Of the 
1·65 billion (1·62–1·67) global YLLs in 2017, 35·1% 
(34·2–36·2) were from CMNN causes, 53·0% (52·2–53·8) 
were from NCDs, and the remaining 11·9% (11·5–12·1) 
were from injuries. Both the number of deaths and death 
rates from CMNN causes decreased from 2007 to 2017, by 
22·2% (20·0–24·0) in terms of total deaths and by 31·8% 
(30·1–33·3) in terms of mortality rate. Decreases in the 
number and rate of YLLs from CMNN causes were 
similar in magnitude (30·4% [28·2–32·4] decrease in 
YLLs; 35·4% [33·4–37·3] decrease in YLL rate) over the 
same time period. By contrast, total deaths from NCD 
causes increased between 2007 and 2017 by 22·7% 
(21·5–23·9) and total YLLs from NCD causes increased 
by 13·6% (12·2–14·9), repre senting an additional 7·61 
million (7·20–8·01) deaths and 105 million (94·3–114·0) 
YLLs estimated in 2017. Rates of both deaths and YLLs 
from NCD causes decreased over the same time period, 
by 7·9% (7·0–8·8) to 536·1 deaths (528·4–542·2) per 
100 000, with a 9·6% (8·6–10·7) decrease in the YLL rate 
to 11 100 YLLs (10 900–11 300) per 100 000 in 2017. Total 
deaths from injuries varied little between 2007 and 2017, 
with an increase of 2·3% (0·5–4·0) to 4·48 million 
(4·33–4·59) deaths, while death rates from injury 
decreased by 13·7% (12·2–15·1) to 57·9 deaths 
(55·9–59·2) per 100 000 in 2017. Decreases in the number 
of YLLs (by 6·4% [4·8–7·8] to 195 million [189–200] YLLs 
in 2017) and YLL rate (by 16·9% [15·3–18·2] to 
2550 [2460–2610] YLLs per 100 000 in 2017) for injuries 
were estimated during the same period.
Communicable, maternal, neonatal, and nutritional diseases
The overall decrease in communicable causes of death 
included reductions in some of the largest contributors to 
global mortality, including HIV/AIDS, tuberculosis, 
diarrhoeal diseases, and malaria (table 1). The peak in 
HIV/AIDS mortality occurred in 2006 with 1·95 million 
deaths (95% UI 1·87–2·04) and a rate of 28·8 deaths 
(27·7–30·1) per 100 000, but between 2007 and 2017, total 
mortality from HIV/AIDS decreased from 1·92 million 
(1·84–2·00) deaths to 0·954 million (0·907–1·01) deaths 
with a commensurate decrease (56·5% [54·7–58·0]) in the 
mortality rate from 27·9 deaths (26·8–29·1) per 100 000 in 
2007 to 12·1 deaths (11·5–12·9) per 100 000 in 2017. 
Although tuberculosis caused an estimated 1·18 million 
(1·13–1·25) deaths in 2017, this was nonetheless a decrease 
of 14·9% (10·3–18·2) from levels in 2007, when 
tuberculosis caused 1·39 million (1·34–1·46) deaths. Drug-
susceptible tuberculosis deaths were the largest component 
of tuberculosis deaths in 2017 (88·2% [81·4–93·3]) and 
decreased the most since 2007 (15·5% [8·6–22·3]) in 
comparison with other tuberculosis sub-causes. All 
HIV/AIDS and tuberculosis co-infections also decreased, 
with declines occurring for deaths from HIV/AIDS and 
drug-resistant tuberculosis co-infection (8·3% [–26·8 to 
14·7]), HIV/AIDS and multidrug-resistant tuber cu losis co-
infection (52·2% [33·2–66·4]), and HIV/AIDS and drug-
susceptible tuberculosis co-infection (55·4% [51·6–58·4]). 
The total number of deaths from diarrhoeal diseases 
decreased by 16·6% (6·7–25·3) between 2007 and 2017, 
from 1·88 million (1·53–2·47) deaths in 2007 to 
1·57 million (1·18–2·19) deaths in 2017. There was a 
parallel decrease in the death rate (30·2% [22·7–36·1]) 
from diarrhoeal diseases, from 31·0 deaths (25·0–40·9) 
per 100 000 in 2007 to 21·6 deaths (16·4–29·7) per 100 000 
in 2017. There were 620 000 deaths (440 000–840 000) from 
malaria in 2017, a decrease of 30·8% (20·8–39·4) from 
2007 when 896 000 deaths (664 000–1 180 000) were 
estimated. Deaths due to measles decreased by 57·0% 
(51·9–61·9) from 222 000 deaths (82 300–457 000) in 2007 
to 95 300 (34 500–205 000) in 2017. Invasive non-typhoidal 
salmonella deaths were estimated to have decreased from 
71 900 deaths (42 200–116 000) in 2007 to 59 100 deaths 
(33 300–98 100) in 2017. A notable exception to the estimated 
improvements for communicable diseases occurred for 
dengue, where deaths increased by 65·5% (21·7–99·7) 
from 24 500 (11 500–29 600) in 2007 to 40 500 (17 600–49 800) 
in 2017, with a similar increase in mortality rate (40·7% 
[3·6–69·7], from 0·4 deaths [0·2–0·5] per 100 000 in 2007 
to 0·5 deaths [0·2–0·7] per 100 000 in 2017).
At Level 2 of the GBD cause hierarchy, there were 
1·98 million (95% UI 1·89–2·06) deaths from maternal 
For the online results tool see 
http://ghdx.healthdata.org/gbd-
results-tool
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